<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Control</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Control</journal-id><journal-id journal-id-type="pmc-domain-id">3344</journal-id><journal-id journal-id-type="pmc-domain">ccon</journal-id><journal-id journal-id-type="publisher-id">CCX</journal-id><journal-title-group><journal-title>Cancer Control : Journal of the Moffitt Cancer Center</journal-title></journal-title-group><issn pub-type="ppub">1073-2748</issn><issn pub-type="epub">1526-2359</issn><publisher><publisher-name>SAGE Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11526253</article-id><article-id pub-id-type="pmcid-ver">PMC11526253.1</article-id><article-id pub-id-type="pmcaid">11526253</article-id><article-id pub-id-type="pmcaiid">11526253</article-id><article-id pub-id-type="pmid">39425746</article-id><article-id pub-id-type="doi">10.1177/10732748241290769</article-id><article-id pub-id-type="publisher-id">10.1177_10732748241290769</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title>Prescription Opioid Use before and after Diagnosis of Cancer Among Older Cancer Survivors With Non-Cancer Chronic Pain Conditions (NCPCs): An Application of Group-Based Trajectory Modeling (GBTM)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4906-9212</contrib-id><name name-style="western"><surname>Safarudin</surname><given-names initials="R">Rudi</given-names></name><xref rid="aff1-10732748241290769" ref-type="aff">1</xref><xref rid="aff2-10732748241290769" ref-type="aff">2</xref><xref rid="aff3-10732748241290769" ref-type="aff">3</xref><xref rid="corresp1-10732748241290769" ref-type="corresp"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6998-2650</contrib-id><name name-style="western"><surname>LeMasters</surname><given-names initials="T">Traci</given-names></name><xref rid="aff2-10732748241290769" ref-type="aff">2</xref><xref rid="aff4-10732748241290769" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5983-8965</contrib-id><name name-style="western"><surname>Khan</surname><given-names initials="S">Salman</given-names></name><xref rid="aff5-10732748241290769" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8311-1360</contrib-id><name name-style="western"><surname>Sambamoorthi</surname><given-names initials="U">Usha</given-names></name><xref rid="aff2-10732748241290769" ref-type="aff">2</xref><xref rid="aff6-10732748241290769" ref-type="aff">6</xref></contrib><aff id="aff1-10732748241290769"><label>1</label>Department of Pharmacy, Faculty of Mathematics and Natural Sciences, <institution-wrap><institution-id institution-id-type="Ringgold">175472</institution-id><institution content-type="university">Tadulako University</institution></institution-wrap>, Palu, Central Sulawesi, Indonesia</aff><aff id="aff2-10732748241290769"><label>2</label>Department of Pharmaceutical Systems and Policy, School of Pharmacy, <institution-wrap><institution-id institution-id-type="Ringgold">5631</institution-id><institution content-type="university">West Virginia University</institution></institution-wrap>, Morgantown, WV, USA</aff><aff id="aff3-10732748241290769"><label>3</label>Prescription Drug Misuse Education and Research (PREMIER) Center, College of Pharmacy, <institution-wrap><institution-id institution-id-type="Ringgold">14743</institution-id><institution content-type="university">University of Houston</institution></institution-wrap>, Houston, TX, USA</aff><aff id="aff4-10732748241290769"><label>4</label>OPEN Health, Bethesda, MD, USA</aff><aff id="aff5-10732748241290769"><label>5</label>Department of Internal Medicine, School of Medicine, <institution-wrap><institution-id institution-id-type="Ringgold">12334</institution-id><institution content-type="university">University of Texas Southwestern Medical Center</institution></institution-wrap>, Dallas, TX, USA</aff><aff id="aff6-10732748241290769"><label>6</label>Department of Pharmacotherapy, College of Pharmacy, <institution-wrap><institution-id institution-id-type="Ringgold">12376</institution-id><institution content-type="university">University of North Texas Health Sciences Center</institution></institution-wrap>, Fort Worth, TX, USA</aff></contrib-group><author-notes><corresp id="corresp1-10732748241290769">Rudi Safarudin, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, Tadulako University, Jl. Soekarno Hatta Km. 9, Palu, Central Sulawesi, Indonesia, 94148. Email: <email>rudi17safarudin@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="collection"><season>Jan-Dec</season><year>2024</year></pub-date><volume>31</volume><issue-id pub-id-type="pmc-issue-id">453589</issue-id><elocation-id>10732748241290769</elocation-id><history><date date-type="received"><day>12</day><month>9</month><year>2023</year></date><date date-type="rev-recd"><day>16</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>24</day><month>9</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>19</day><month>10</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>31</day><month>10</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-11-01 10:25:15.080"><day>01</day><month>11</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder content-type="sage">SAGE Publications Inc, unless otherwise noted. Manuscript content on this site is licensed under Creative Common Licences</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_10732748241290769.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="1290769.pdf"/><abstract><sec><title>Background</title><p>Prescription opioids are essential in managing pain among adults with chronic pain conditions. However, persistent use over time can lead to negative health consequences. Identifying individuals with persistent use over time and their characteristics can inform clinical decision-making and aid in reducing the risk of abuse and overdose deaths.</p></sec><sec><title>Objective</title><p>This study aims to examine trajectories of prescription opioid use over time and factors associated with these trajectories among older cancer survivors with any non-cancer pain conditions (NCPC).</p></sec><sec><title>Methods</title><p>We conducted a retrospective cohort study design with longitudinal data of older (age at cancer diagnosis &#8805;67&#160;years) cancer (incident breast, colorectal, and prostate cancers, or non-Hodgkin lymphoma) survivors with any NCPC. Data were derived from the 2007-2015 linked Surveillance, Epidemiology, and End Results (SEER)-Medicare dataset (N = 35,071). Group-Based Trajectory Modeling (GBTM) was used to identify homogeneous subgroups (distinct trajectories) of individuals based on every 90-day prescription opioid use during pre-cancer diagnosis (t<sub>1</sub>-t<sub>4</sub>), acute cancer treatment (t<sub>5</sub>-t<sub>8</sub>), and post-cancer treatment (t<sub>9</sub>-t<sub>12</sub>) periods. Biological factors, social determinants of health (SDoH), physical and mental health, medication use, health care use, and external factors associated with a trajectory membership were analyzed with multivariable multinomial logistic regressions.</p></sec><sec><title>Results</title><p>Four distinct trajectories of opioid use were identified: (1) increase-decrease use (6.1%); (2) short-term use after cancer diagnosis (40.6%); (3) low-use (41.0%); and (4) persistent use (12.3%). In the fully-adjusted multinomial logistic regression, the SDoH such as Non-Hispanic Black [adjusted odds ratios (AOR) = 1.69; 95%CI = 1.48, 1.93)] and rural residence (AOR = 1.49; 95%CI = 1.15, 1.94)], comorbid anxiety (AOR = 1.33; 95%CI = 1.18, 1.51), and medication use (NSAIDs - AOR = 1.20; 95%CI = 1.10, 1.30) were associated with membership in the persistent use group. Persistent use was less likely among those with higher fragmented care index (AOR = 0.95, 95%CI = 0.93, 0.97) and those living in counties with higher Medicare advantage penetration (AOR = 0.96; 95%CI = 0.95, 0.97).</p></sec><sec><title>Conclusions</title><p>One in eight older adults had persistent opioid use over time. The profile characteristics of this group were different from the other trajectory groups. Policies and programs to reduce chronic opioid use need to consider the intra- and inter-individual variability to reduce opioid-related morbidity and mortality.</p></sec></abstract><abstract abstract-type="plain-language-summary"><title>Plain Language Summary</title><p>This study looked at how older adults with cancer and long-term non-cancer pain used prescription opioids before and after their cancer diagnosis. The goal was to understand the patterns of opioid use over time and identify factors linked to long-term use. We analyzed data from over 35,000 cancer survivors with chronic pain conditions, focusing on their opioid prescriptions for the year before and two years after their cancer diagnosis. We identified four main patterns (or &#8220;trajectories&#8221;) of opioid use: (1) Increase-decrease use (6%): Use increased but later decreased; (2) Short-term use after cancer diagnosis (41%): Opioid use was brief and followed the cancer diagnosis; (3) Low-use (41%): Very little opioid use; (4) Persistent use (12%): Consistent use over time. Certain groups, including Black individuals, rural residents, and those with anxiety, were more likely to have persistent opioid use. People with more fragmented healthcare or living in areas with more Medicare Advantage coverage were less likely to stay on opioids long-term. The study highlights that 1 in 8 older cancer survivors continued using opioids for an extended period. Tailored programs are needed to address individual differences in order to reduce the risks of opioid misuse and overdose.</p></abstract><kwd-group><kwd>opioids</kwd><kwd>persistent use</kwd><kwd>trajectory</kwd><kwd>group-based trajectory modeling</kwd><kwd>chronic pain</kwd><kwd>cancer</kwd></kwd-group><funding-group specific-use="FundRef"><award-group id="award1-10732748241290769"><funding-source id="funding-source1-10732748241290769"><institution-wrap><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id rid="funding-source1-10732748241290769">1OT2OD032581</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts10</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec6-10732748241290769"><title>Introduction</title><p>Among cancer survivors, prescription opioids continue to remain as a primary therapy to treat pain associated with cancer growth, surgical, and other cancer treatments.<sup><xref rid="bibr1-10732748241290769" ref-type="bibr">1</xref>,<xref rid="bibr2-10732748241290769" ref-type="bibr">2</xref></sup> Furthermore, a subpopulation that may have high rates of prescription opioid use is individuals with non-cancer pain conditions (NCPC) for their pain management. Nearly one in two adults (44%) with NCPCs filled at least one opioid prescription in a year,<sup>
<xref rid="bibr3-10732748241290769" ref-type="bibr">3</xref>
</sup> and 14% reported long-term use.<sup>
<xref rid="bibr4-10732748241290769" ref-type="bibr">4</xref>
</sup> Moreover, older adults are more prone to use prescription opioids.<sup><xref rid="bibr5-10732748241290769" ref-type="bibr">5</xref><xref rid="bibr6-10732748241290769" ref-type="bibr"/>-<xref rid="bibr7-10732748241290769" ref-type="bibr">7</xref></sup> Ramachandran and colleagues found a significant increase in new prescriptions of opioids annually from 2013 to 2015 (from 6.6% to 10.3%) among older Medicare beneficiaries.<sup>
<xref rid="bibr8-10732748241290769" ref-type="bibr">8</xref>
</sup></p><p>During the cancer treatment period, older individuals with both NCPCs and cancer may require higher doses of opioids for a longer term, even in the absence of disease progression due to opioid-induced hyperalgesia and the effects of tolerance.<sup><xref rid="bibr9-10732748241290769" ref-type="bibr">9</xref>,<xref rid="bibr10-10732748241290769" ref-type="bibr">10</xref></sup> Clinical guidelines recommend that opioids should be prescribed for only short-term periods and should be tapered off to prevent the prescription opioids from triggering opioid use disorders.<sup><xref rid="bibr11-10732748241290769" ref-type="bibr">11</xref>,<xref rid="bibr12-10732748241290769" ref-type="bibr">12</xref></sup> However, research has shown that many patients persist in long-term prescription opioid use. For example, a study on older Medicare beneficiaries with NCPCs found that 25.0% of patients were being prescribed opioids at a consistently moderate dose over a period of six months,<sup>
<xref rid="bibr13-10732748241290769" ref-type="bibr">13</xref>
</sup> while among hospitalized opioid users (mean age = 59.2&#160;years, SD = 14.4), 19.2% remained on the stable high dose for a year since the day of the first hospital opioid prescription.<sup>
<xref rid="bibr14-10732748241290769" ref-type="bibr">14</xref>
</sup></p><p>Opioid-trajectory-wise, only one study was found conducted on older adults with NCPCs. It identified four prescription opioid dose trajectories: gradual dose discontinuation (23.5%), gradual dose increase (30.3%), consistent low dose (24.3%), and consistent moderate dose (22.0%).<sup>
<xref rid="bibr13-10732748241290769" ref-type="bibr">13</xref>
</sup> Of these four patterns, older beneficiaries with a gradual dose increase had an increased risk of having opioid adverse effects compared to those with opioid dose discontinuation.<sup>
<xref rid="bibr13-10732748241290769" ref-type="bibr">13</xref>
</sup></p><p>To date, no investigations have systematically characterized the distinct trajectories of prescription opioid use over time before and after cancer diagnosis or the factors associated with the trajectories among older adults with any NCPC. Therefore, this study aims to identify the opioid use trajectories and to profile the characteristics associated with these trajectories before and after cancer diagnosis utilizing the population-based, Surveillance, Epidemiology, and End Results (SEER)-Medicare claims linked database in the US. This study can inform clinical decision-making to reduce the potential for abuse and the risk of opioid-related overdose deaths.</p></sec><sec sec-type="methods" id="sec7-10732748241290769"><title>Methods</title><sec id="sec8-10732748241290769"><title>Study Design</title><p>We employed a retrospective cohort study design with longitudinal data. The cohort consisted of older adults (age &gt;67 years at the time of cancer diagnosis) with any NCPC and an incident primary cancer (breast, prostate, colorectal cancer, or Non-Hodgkin Lymphoma (NHL)) between 2009 and 2013. The NCPCs consisted of headaches, nervous system disorders, systemic lupus erythematosus, osteoarthritis, rheumatoid arthritis, gout, spondylosis, fractures, and other musculoskeletal and connective tissue disorders. These NCPCs were carefully selected based on their prevalence among the elderly population, as reflected in the dataset utilized in this study.</p><p>We selected age 67&#160;years or older at cancer diagnosis to allow for Medicare enrollment 2-year before cancer diagnosis. We observed the selected individuals for 48 months consisting of a 24-month pre-cancer diagnosis (12&#160;months of NCPC identification +12&#160;months of opioid use and other independent variable data collection) and a 24-month post-cancer diagnosis period (24&#160;months of opioid use follow-up).</p><p>West Virginia University&#8217;s Institutional Review Board (IRB) approved this study's ethics with Acknowledgement of Not Human Subjects Research (NHSR) - protocol # 2109427002 - as no individually identifiable private information was involved.</p></sec><sec id="sec9-10732748241290769"><title>Data Sources</title><p>This study utilized the linked SEER-Medicare database. This linked database merged large population-based data sources that provide patient- (SEER-registry and Medicare claims), zip code- (census track), and county-level (Area Health Resource File) data. The population-based SEER cancer registry contains demographic and clinical information about the cancer diagnosis, including type, subtype, stage, tumor size, lymph node involvement, tumor receptors and other prognostic features, and cause of death.<sup>
<xref rid="bibr15-10732748241290769" ref-type="bibr">15</xref>
</sup> Medicare claims provide data on the date of diagnosis, presence of other health conditions, services and treatments for cancer and non-cancer conditions, health care expenditures, and beneficiary enrollment information.<sup>
<xref rid="bibr15-10732748241290769" ref-type="bibr">15</xref>
</sup> We obtained county-level information on population characteristics, economics, health care professions, health professions training, health facilities, hospital utilization and expenditures, and the environment from the area health resource files (AHRF).<sup>
<xref rid="bibr16-10732748241290769" ref-type="bibr">16</xref>
</sup> The zip code-level neighborhood profiles of economic and demographic data were derived from the census tract files.</p></sec><sec id="sec10-10732748241290769"><title>Identification of NCPCs</title><p>We identified the older individuals (age at cancer diagnosis &#8805;67&#160;years) with any NCPC before the cancer diagnosis date using one inpatient or two outpatient visits for NCPC. NCPC conditions were identified based on the AHRQ Clinical Classifications Software (CCS) codes mapped to ICD-9 and ICD-10.<sup><xref rid="bibr17-10732748241290769" ref-type="bibr">17</xref>,<xref rid="bibr18-10732748241290769" ref-type="bibr">18</xref></sup> To preserve temporality, opioid use was identified after NCPC diagnosis. Thus, the NCPC identification period was between 24 and 12&#160;months before cancer diagnosis or 12&#160;months before opioid use.</p></sec><sec id="sec11-10732748241290769"><title>Identification of Older Adults with Cancer</title><p>We included the older adults diagnosed with the following incident and primary cancers: breast, colorectal cancer, prostate, or NHL between 2009 and 2013. These cancers were identified from the SEER-cancer registry.</p></sec><sec id="sec12-10732748241290769"><title>Inclusion and Exclusion Criteria</title><p>We required the study cohort to be continuously enrolled in Fee-for-Service Parts A and B for the entire observation period (48&#160;months), continuously enrolled in Part D (Medicare Prescription Drug Program) for 36 months (12&#160;months before cancer and 24&#160;months after cancer diagnosis). We excluded individuals who were diagnosed with cancer at autopsy. The final study cohort consisted of 35,071 older adults with any NCPC and primary incident breast cancer (42.0%), prostate (32.8%), colorectal (17.0%) cancers, or NHL (8.2%).</p></sec><sec id="sec13-10732748241290769"><title>Measures</title><sec id="sec14-10732748241290769"><title>Dependent Variable: Opioid Use Every 90 days (yes/no)</title><p>We measured any prescription opioid use every 90 days as a dichotomous variable (yes/no) during the 36 months (12&#160;months before cancer diagnosis and 24 months after cancer diagnosis). The opioids were identified using the generic names (GNN)<sup>
<xref rid="bibr19-10732748241290769" ref-type="bibr">19</xref>
</sup> from the Medicare Part D prescription events file. The opioids included are codeine, dihydrocodeine, hydrocodone, oxycodone, hydromorphone, oxymorphone, morphine, tramadol, buprenorphine, pentazocine, fentanyl, sufentanil, methadone, and meperidine.</p></sec><sec id="sec15-10732748241290769"><title>Independent Variables</title><p>All independent variables were measured 12&#160;months before cancer diagnosis. The selection of independent variables was guided by the conceptual framework adapted from the modified Determinants of Health model by Park et al.<sup>
<xref rid="bibr20-10732748241290769" ref-type="bibr">20</xref>
</sup> This model suggests that health is multifactorial, and that the health of individuals may be considered to be the result of interactions of many variables. Using this model, we classified the independent variables into the following domains: biological, social determinants of health (SDoH), physical health, mental health, health care use, medication use, and external factors.</p><p>The biological factors included age at cancer diagnosis and sex (male or female). SDoH factors encompassed zip code-level percentages of residents living below poverty and those with a college education, patient-level race and ethnicity (non-Hispanic white, non-Hispanic black, Latino/Hispanic, or others), Medicare and Medicaid dual eligibility, marital status, rural-urban commuting area (metro, urban, or rural), and geographic region (Northeast, South, North-Central, or West). Physical health factors included cancer types and stages, physical comorbidities (&#8805;2) (thyroid, asthma, coronary artery disease, arrhythmia, diabetes, congestive heart failure, chronic kidney disease, chronic obstructive pulmonary disease, dementia, hepatitis, hyperlipidemia, HIV, hypertension, osteoporosis, stroke). Mental health was measured by diagnosed depression, anxiety, and substance abuse. Medication use consisted of polypharmacy (&#8805;6 drugs, excluding opioids) and the use of NSAIDs, steroids, antidepressants, and benzodiazepines. Health care use comprised visits to pain specialists, anesthesiologists, primary care physicians (PCP), and fragmentation care index (FCI). The FCI was computed based on a modified version of a validated continuity of care index,<sup>
<xref rid="bibr21-10732748241290769" ref-type="bibr">21</xref>
</sup> based on the number of health care visits, providers seen, and the proportion of visits with each provider. The ranges of FCI were from 0 (all visits with the same provider) to 10 (each visit with a different provider), and higher values suggest fragmented care or care discontinuation. For ease of interpretation, we multiplied the FCI by 10. External factors included diagnosis year and market characteristics, specifically the county-level percentages of Medicare Advantage penetration. The Medicare Advantage penetration variable was determined using the county data from SEER-Medicare linked to an external source of AHRF data.</p></sec></sec><sec id="sec16-10732748241290769"><title>Statistical Analyses</title><sec id="sec17-10732748241290769"><title>Identification of Opioid Use Trajectories</title><p>GBTM groups individuals into subgroups that show statistically similar patterns over time for the primary variable under consideration (in our case, opioid use) based on the data.<sup>
<xref rid="bibr22-10732748241290769" ref-type="bibr">22</xref>
</sup> It is an alternative approach to multi-level modeling used to study the intra- and inter-individual variabilities.<sup>
<xref rid="bibr23-10732748241290769" ref-type="bibr">23</xref>
</sup> GBTM is a statistical method to identify individuals&#8217; subgroups based on time functions as determined by maximum likelihood estimation. The GBTM assigns group membership by ranking probabilities and assigning members with the highest probability to a specific group.</p><p>We followed the best practices of GBTM to identify opioid use trajectories.<sup>
<xref rid="bibr22-10732748241290769" ref-type="bibr">22</xref>
</sup> For example, we determined the necessary number of groups before choosing the optimal functional model for each group. We selected the optimal number of groups based on clinical meaningfulness, distinct patterns, and statistical significance. We explored different combinations of linear, quadratic, cubic, or quartic terms.</p><p>After identifying the opioid use trajectory patterns, we used multivariable multinomial logistic regressions (MLR) (covariate adjustment method) to analyze the unadjusted and adjusted associations of the study cohort&#8217;s characteristics with the trajectory groups. The utilization of the MLR covariate adjustment method was intended to reduce potential selection bias in this study. All data management and all analyses except GBTM were conducted with SAS 9.4 (SAS Institute Inc., Cary, NC). Stata 14 (Stata Corp LLC, College Station, TX) was used for GBTM.</p><p>The reporting of this study has followed relevant Equator guidelines,<sup>
<xref rid="bibr24-10732748241290769" ref-type="bibr">24</xref>
</sup> and complied with The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.<sup>
<xref rid="bibr25-10732748241290769" ref-type="bibr">25</xref>
</sup></p></sec></sec></sec><sec sec-type="results" id="sec18-10732748241290769"><title>Results</title><sec id="sec19-10732748241290769"><title>Study Cohort Characteristics</title><p>A majority of the study cohort was female (58.5%), Non-Hispanic White (75.9%), and living in metropolitan areas (84.2%). An overwhelming majority (79.3%) had pre-existing physical comorbidities (excluding NCPCs). Of all older adults, 9.1% had anxiety, and 29.3%, 46.3%, 23.7% were prescribed NSAIDs, steroids, and antidepressants, respectively. The fragmented care index averaged 0.73 with SD = 0.248. The mean Medicare Advantage Penetration rate was 24.99% with SD = 12.84%.</p></sec><sec id="sec20-10732748241290769"><title>Opioid Use Trajectories</title><p>The final GBTM resulted in four distinct patterns of opioid use that were anchored to cancer diagnosis and treatment. For example, the use patterns followed three distinct time periods: pre-cancer diagnosis (t<sub>1</sub>-t<sub>4</sub>), acute cancer treatment (t<sub>5</sub>-t<sub>8</sub>), and post-acute cancer treatment (t<sub>9</sub>-t<sub>12</sub>). The trajectories were: (1) increase-decrease use (6.1%); (2) short-term use after cancer diagnosis (40.6%); 3); low-use (41.0%); and (4) persistent use (12.3%) (refer to <xref rid="table1-10732748241290769" ref-type="table">Table 1</xref>). The selection of these groups was based on the following criteria: (1) significant <italic toggle="yes">P</italic>-values (&lt;0.05) for the highest-order polynomial parameter; (2) at least 5% of the population assigned to each trajectory group; (3) no polynomial overfitting; and (4) clinically meaningful grouping.<sup><xref rid="bibr22-10732748241290769" ref-type="bibr">22</xref>,<xref rid="bibr26-10732748241290769" ref-type="bibr">26</xref>,<xref rid="bibr27-10732748241290769" ref-type="bibr">27</xref></sup> The final trajectory model satisfied Nagin&#8217;s diagnostic criteria of the &#8220;average of posterior probabilities (groupAPP) &gt; 0.7&#8243; for all groups.<sup><xref rid="bibr26-10732748241290769" ref-type="bibr">26</xref>,<xref rid="bibr27-10732748241290769" ref-type="bibr">27</xref></sup><table-wrap position="float" id="table1-10732748241290769" orientation="portrait"><label>Table 1.</label><caption><p>Statistics of Opioid Use Trajectory Groups by GBTM Among Older Medicare Beneficiaries With Any NCPC, 12&#160;Months before and 24&#160;Months after Incident Primary Breast, Colorectal, Prostate Cancers, or NHL Cancers, and Non-hodgkin Lymphoma (NHL) Linked Surveillance, Epidemiology, and End Results (SEER) and Medicare, 2007-2015.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="table1-10732748241290769" position="float" orientation="portrait" xlink:href="10.1177_10732748241290769-table1.jpg"/><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Estimate</th><th align="center" rowspan="1" colspan="1">Standard Error</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-Values</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="3" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Intercept</td><td align="char" char="." rowspan="1" colspan="1">&#8722;4.36182</td><td align="char" char="." rowspan="1" colspan="1">0.14503</td><td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Linear</td><td align="char" char="." rowspan="1" colspan="1">1.48009</td><td align="char" char="." rowspan="1" colspan="1">0.04219</td><td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Quadratic</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.09873</td><td align="char" char="." rowspan="1" colspan="1">0.00269</td><td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="3" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Intercept</td><td align="char" char="." rowspan="1" colspan="1">&#8722;78.83808</td><td align="char" char="." rowspan="1" colspan="1">2.02968</td><td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Linear</td><td align="char" char="." rowspan="1" colspan="1">30.66687</td><td align="char" char="." rowspan="1" colspan="1">0.75859</td><td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Quadratic</td><td align="char" char="." rowspan="1" colspan="1">&#8722;2.98561</td><td align="char" char="." rowspan="1" colspan="1">0.07055</td><td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="3" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Intercept</td><td align="char" char="." rowspan="1" colspan="1">&#8722;2.14057</td><td align="char" char="." rowspan="1" colspan="1">0.02536</td><td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Linear</td><td align="char" char="." rowspan="1" colspan="1">0.45497</td><td align="char" char="." rowspan="1" colspan="1">0.00920</td><td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Quadratic</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.04428</td><td align="char" char="." rowspan="1" colspan="1">0.00074</td><td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="3" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Intercept</td><td align="char" char="." rowspan="1" colspan="1">1.46626</td><td align="char" char="." rowspan="1" colspan="1">0.07452</td><td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Linear</td><td align="char" char="." rowspan="1" colspan="1">0.73675</td><td align="char" char="." rowspan="1" colspan="1">0.02190</td><td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Quadratic</td><td align="char" char="." rowspan="1" colspan="1">&#8722;0.08054</td><td align="char" char="." rowspan="1" colspan="1">0.00156</td><td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td></tr></tbody></table><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" colspan="2" rowspan="1">Group membership</th><th align="center" rowspan="1" colspan="1">% of Pop Assigned</th><th align="center" rowspan="1" colspan="1">Standard Error</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-Values</th><th align="center" rowspan="1" colspan="1">GroupAPP</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Increase-decrease use</td><td align="char" char="." rowspan="1" colspan="1">6.1</td><td align="char" char="." rowspan="1" colspan="1">0.23991</td><td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td><td align="char" char="." rowspan="1" colspan="1">0.821366</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Short-term use after cancer diagnosis</td><td align="char" char="." rowspan="1" colspan="1">40.6</td><td align="char" char="." rowspan="1" colspan="1">0.33671</td><td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td><td align="char" char="." rowspan="1" colspan="1">0.827613</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Low use</td><td align="char" char="." rowspan="1" colspan="1">41.0</td><td align="char" char="." rowspan="1" colspan="1">0.36048</td><td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td><td align="char" char="." rowspan="1" colspan="1">0.945373</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Persistent use</td><td align="char" char="." rowspan="1" colspan="1">12.3</td><td align="char" char="." rowspan="1" colspan="1">0.20208</td><td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td><td align="char" char="." rowspan="1" colspan="1">0.965117</td></tr><tr><td align="left" colspan="2" rowspan="1">Entropy = 0.806</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Note: The final model was run with the all-quadratic polynomial combination.</p></fn><fn><p>Based on 35,071 adults with NCPCs 67 years or older, diagnosed with incident primary breast, prostate, colorectal cancers, and NHL between 2009 and 2015, continuously enrolled in Fee-for-Service Medicare Parts A and B for 24 months, and continuously enrolled in Medicare part D for 12 months before and 24 months after cancer diagnosis. Group differences by opioid use categories were tested with Chi-Square test.</p></fn><fn><p>Abbreviations: GBTM: Group-Based Trajectory Modeling, GroupAPP: average posterior probability for each group, OCC: odds of correct classification, NHL: Non-Hodgkin Lymphoma.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec21-10732748241290769"><title>Opioid Use Trajectories</title><p><xref rid="fig1-10732748241290769" ref-type="fig">Figure 1</xref> displays the trajectories of opioid use over time estimated from the GBTM. During the pre-cancer diagnosis period (t<sub>1</sub> through t<sub>4</sub>), the following groups: (1) &#8220;increase-decrease use&#8221;; (2) &#8220;short-term use after cancer diagnosis&#8221;; and (3) &#8220;low use&#8221; had low probability of any opioid use. The opioid use pattern for the &#8220;increase-decrease use&#8221; group consisted of a gradually increasing probability of opioid use before cancer diagnosis (t<sub>1</sub>-t<sub>4</sub>), with the highest probability during the acute cancer treatment (t<sub>5</sub>-t<sub>8</sub>) and tapering off during the post-acute cancer treatment (t<sub>9</sub>-t<sub>12</sub>). The group with &#8220;short-term use after cancer diagnosis&#8221; did not have any opioid use either before a diagnosis of cancer (t<sub>1</sub>-t<sub>4</sub>) or during the post-acute cancer treatment phase (t<sub>9</sub>-t<sub>12</sub>) and had a high probability of opioid use during the acute cancer treatment phase (t<sub>5</sub>-t<sub>8</sub>). The &#8220;low-use&#8221; group had a consistently low probability of any opioid use before cancer diagnosis (t<sub>1</sub>-t<sub>4</sub>) and during the post-acute cancer treatment (t<sub>9</sub>-t<sub>12</sub>) period.<fig position="float" fig-type="figure" id="fig1-10732748241290769" orientation="portrait"><label>Figure 1.</label><caption><p>Trajectories of any opioid use among older medicare beneficiaries with any NCPC, 12&#160;months before and 24&#160;months after incident primary breast, colorectal, prostate cancers, or non-hodgkin lymphoma (NHL) linked surveillance, epidemiology, and end results (SEER) and medicare, 2007-2015.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_10732748241290769-fig1.jpg"/></fig></p><p>On the other hand, the &#8220;persistent use&#8221; group was more likely to use opioids before cancer diagnosis (t<sub>1</sub>-t<sub>4</sub>) and during the acute treatment phase (t<sub>5</sub>-t<sub>8</sub>). In this group, although the probability of opioid use declined, it never reached the lower probability of the other groups. For all groups, the probability of opioid use peaked immediately after cancer diagnosis (t<sub>5</sub>).</p></sec><sec id="sec22-10732748241290769"><title>Associations of Independent Variables with Opioid Use Trajectory Groups</title><p>Before computing the Odds Ratios, we explored the correlation between the independent variables and the opioid use trajectory groups descriptively listed in <xref rid="table2-10732748241290769" ref-type="table">Table 2</xref>. Subsequently, the unadjusted odds ratios (UOR) and adjusted odds ratios (AOR) (with &#8220;low use&#8221; as the reference) from the multinomial logistic regressions on opioid use trajectory groups are summarized in <xref rid="table3-10732748241290769" ref-type="table">Tables 3</xref> and <xref rid="table4-10732748241290769" ref-type="table">4</xref>, respectively.<table-wrap position="float" id="table2-10732748241290769" orientation="portrait"><label>Table 2.</label><caption><p>Description of Older Medicare Beneficiaries with any NCPC Diagnosed with Breast, Colorectal, Prostate Cancers, or NHL by Opioid Use Trajectory Groups Linked Surveillance, Epidemiology, and End Results (SEER) and Medicare, 2007-2015.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="table2-10732748241290769" position="float" orientation="portrait" xlink:href="10.1177_10732748241290769-table2.jpg"/><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Increase-Decrease Use</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">Short-Term Use After Cancer Diagnosis</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">Low Use</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">Persistent Use</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">Sig</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">All</td><td align="left" rowspan="1" colspan="1">2,150</td><td align="left" rowspan="1" colspan="1">6.1</td><td align="left" rowspan="1" colspan="1">14,244</td><td align="left" rowspan="1" colspan="1">40.6</td><td align="left" rowspan="1" colspan="1">14,371</td><td align="left" rowspan="1" colspan="1">41.0</td><td align="left" rowspan="1" colspan="1">4,306</td><td align="left" rowspan="1" colspan="1">12.3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="9" rowspan="1">Sex</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Female</td><td align="left" rowspan="1" colspan="1">1,373</td><td align="left" rowspan="1" colspan="1">6.7</td><td align="left" rowspan="1" colspan="1">8,138</td><td align="left" rowspan="1" colspan="1">39.6</td><td align="left" rowspan="1" colspan="1">8,256</td><td align="left" rowspan="1" colspan="1">40.2</td><td align="left" rowspan="1" colspan="1">2,760</td><td align="left" rowspan="1" colspan="1">13.4</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Male</td><td align="left" rowspan="1" colspan="1">777</td><td align="left" rowspan="1" colspan="1">5.3</td><td align="left" rowspan="1" colspan="1">6,106</td><td align="left" rowspan="1" colspan="1">42.0</td><td align="left" rowspan="1" colspan="1">6,115</td><td align="left" rowspan="1" colspan="1">42.0</td><td align="left" rowspan="1" colspan="1">1,546</td><td align="left" rowspan="1" colspan="1">10.6</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="9" rowspan="1">Race and ethnicity</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-hispanic white</td><td align="left" rowspan="1" colspan="1">1,604</td><td align="left" rowspan="1" colspan="1">6.0</td><td align="left" rowspan="1" colspan="1">10,905</td><td align="left" rowspan="1" colspan="1">41.0</td><td align="left" rowspan="1" colspan="1">10,975</td><td align="left" rowspan="1" colspan="1">41.3</td><td align="left" rowspan="1" colspan="1">3,121</td><td align="left" rowspan="1" colspan="1">11.7</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-hispanic black</td><td align="left" rowspan="1" colspan="1">258</td><td align="left" rowspan="1" colspan="1">8.1</td><td align="left" rowspan="1" colspan="1">1,061</td><td align="left" rowspan="1" colspan="1">33.2</td><td align="left" rowspan="1" colspan="1">1,222</td><td align="left" rowspan="1" colspan="1">38.2</td><td align="left" rowspan="1" colspan="1">659</td><td align="left" rowspan="1" colspan="1">20.6</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Latino/hispanic</td><td align="left" rowspan="1" colspan="1">198</td><td align="left" rowspan="1" colspan="1">7.3</td><td align="left" rowspan="1" colspan="1">965</td><td align="left" rowspan="1" colspan="1">35.6</td><td align="left" rowspan="1" colspan="1">1,191</td><td align="left" rowspan="1" colspan="1">43.9</td><td align="left" rowspan="1" colspan="1">356</td><td align="left" rowspan="1" colspan="1">13.1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Other races</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">3.9</td><td align="left" rowspan="1" colspan="1">1,067</td><td align="left" rowspan="1" colspan="1">51.5</td><td align="left" rowspan="1" colspan="1">803</td><td align="left" rowspan="1" colspan="1">38.8</td><td align="left" rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1">5.8</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="9" rowspan="1">Marital status</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Married</td><td align="left" rowspan="1" colspan="1">996</td><td align="left" rowspan="1" colspan="1">5.8</td><td align="left" rowspan="1" colspan="1">7,280</td><td align="left" rowspan="1" colspan="1">42.3</td><td align="left" rowspan="1" colspan="1">7,250</td><td align="left" rowspan="1" colspan="1">42.1</td><td align="left" rowspan="1" colspan="1">1,688</td><td align="left" rowspan="1" colspan="1">9.8</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Wid/Sep/Div</td><td align="left" rowspan="1" colspan="1">756</td><td align="left" rowspan="1" colspan="1">6.7</td><td align="left" rowspan="1" colspan="1">4,262</td><td align="left" rowspan="1" colspan="1">37.9</td><td align="left" rowspan="1" colspan="1">4,453</td><td align="left" rowspan="1" colspan="1">39.6</td><td align="left" rowspan="1" colspan="1">1,775</td><td align="left" rowspan="1" colspan="1">15.8</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Never married</td><td align="left" rowspan="1" colspan="1">208</td><td align="left" rowspan="1" colspan="1">7.1</td><td align="left" rowspan="1" colspan="1">1,171</td><td align="left" rowspan="1" colspan="1">39.8</td><td align="left" rowspan="1" colspan="1">1,147</td><td align="left" rowspan="1" colspan="1">39.0</td><td align="left" rowspan="1" colspan="1">417</td><td align="left" rowspan="1" colspan="1">14.2</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="9" rowspan="1">Substance abuse</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">151</td><td align="left" rowspan="1" colspan="1">8.6</td><td align="left" rowspan="1" colspan="1">407</td><td align="left" rowspan="1" colspan="1">23.2</td><td align="left" rowspan="1" colspan="1">679</td><td align="left" rowspan="1" colspan="1">38.7</td><td align="left" rowspan="1" colspan="1">519</td><td align="left" rowspan="1" colspan="1">29.6</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="left" rowspan="1" colspan="1">1,999</td><td align="left" rowspan="1" colspan="1">6.0</td><td align="left" rowspan="1" colspan="1">13,837</td><td align="left" rowspan="1" colspan="1">41.5</td><td align="left" rowspan="1" colspan="1">13,692</td><td align="left" rowspan="1" colspan="1">41.1</td><td align="left" rowspan="1" colspan="1">3,787</td><td align="left" rowspan="1" colspan="1">11.4</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="9" rowspan="1">Comorbidities (&#8805;2)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1,765</td><td align="left" rowspan="1" colspan="1">6.3</td><td align="left" rowspan="1" colspan="1">11,034</td><td align="left" rowspan="1" colspan="1">39.7</td><td align="left" rowspan="1" colspan="1">11,476</td><td align="left" rowspan="1" colspan="1">41.3</td><td align="left" rowspan="1" colspan="1">3,536</td><td align="left" rowspan="1" colspan="1">12.7</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="left" rowspan="1" colspan="1">385</td><td align="left" rowspan="1" colspan="1">5.3</td><td align="left" rowspan="1" colspan="1">3,210</td><td align="left" rowspan="1" colspan="1">44.2</td><td align="left" rowspan="1" colspan="1">2,895</td><td align="left" rowspan="1" colspan="1">39.9</td><td align="left" rowspan="1" colspan="1">770</td><td align="left" rowspan="1" colspan="1">10.6</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="9" rowspan="1">Depression</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Depression</td><td align="left" rowspan="1" colspan="1">328</td><td align="left" rowspan="1" colspan="1">8.2</td><td align="left" rowspan="1" colspan="1">1,101</td><td align="left" rowspan="1" colspan="1">27.6</td><td align="left" rowspan="1" colspan="1">1,665</td><td align="left" rowspan="1" colspan="1">41.7</td><td align="left" rowspan="1" colspan="1">902</td><td align="left" rowspan="1" colspan="1">22.6</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No depression</td><td align="left" rowspan="1" colspan="1">1,822</td><td align="left" rowspan="1" colspan="1">5.9</td><td align="left" rowspan="1" colspan="1">13,143</td><td align="left" rowspan="1" colspan="1">42.3</td><td align="left" rowspan="1" colspan="1">12,706</td><td align="left" rowspan="1" colspan="1">40.9</td><td align="left" rowspan="1" colspan="1">3,404</td><td align="left" rowspan="1" colspan="1">11.0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="9" rowspan="1">Anxiety</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">248</td><td align="left" rowspan="1" colspan="1">7.8</td><td align="left" rowspan="1" colspan="1">901</td><td align="left" rowspan="1" colspan="1">28.3</td><td align="left" rowspan="1" colspan="1">1,294</td><td align="left" rowspan="1" colspan="1">40.6</td><td align="left" rowspan="1" colspan="1">744</td><td align="left" rowspan="1" colspan="1">23.3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="left" rowspan="1" colspan="1">1,902</td><td align="left" rowspan="1" colspan="1">6.0</td><td align="left" rowspan="1" colspan="1">13,343</td><td align="left" rowspan="1" colspan="1">41.8</td><td align="left" rowspan="1" colspan="1">13,077</td><td align="left" rowspan="1" colspan="1">41.0</td><td align="left" rowspan="1" colspan="1">3,562</td><td align="left" rowspan="1" colspan="1">11.2</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="9" rowspan="1">Prescription NSAIDs</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">836</td><td align="left" rowspan="1" colspan="1">8.1</td><td align="left" rowspan="1" colspan="1">2,906</td><td align="left" rowspan="1" colspan="1">28.3</td><td align="left" rowspan="1" colspan="1">4,712</td><td align="left" rowspan="1" colspan="1">45.9</td><td align="left" rowspan="1" colspan="1">1,813</td><td align="left" rowspan="1" colspan="1">17.7</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="left" rowspan="1" colspan="1">1,314</td><td align="left" rowspan="1" colspan="1">5.3</td><td align="left" rowspan="1" colspan="1">11,338</td><td align="left" rowspan="1" colspan="1">45.7</td><td align="left" rowspan="1" colspan="1">9,659</td><td align="left" rowspan="1" colspan="1">38.9</td><td align="left" rowspan="1" colspan="1">2,493</td><td align="left" rowspan="1" colspan="1">10.1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="9" rowspan="1">Steroids</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1,122</td><td align="left" rowspan="1" colspan="1">6.9</td><td align="left" rowspan="1" colspan="1">5,694</td><td align="left" rowspan="1" colspan="1">35.1</td><td align="left" rowspan="1" colspan="1">7,017</td><td align="left" rowspan="1" colspan="1">43.2</td><td align="left" rowspan="1" colspan="1">2,409</td><td align="left" rowspan="1" colspan="1">14.8</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="left" rowspan="1" colspan="1">1,028</td><td align="left" rowspan="1" colspan="1">5.5</td><td align="left" rowspan="1" colspan="1">8,550</td><td align="left" rowspan="1" colspan="1">45.4</td><td align="left" rowspan="1" colspan="1">7,354</td><td align="left" rowspan="1" colspan="1">39.1</td><td align="left" rowspan="1" colspan="1">1,897</td><td align="left" rowspan="1" colspan="1">10.1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="9" rowspan="1">Antidepressants</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">663</td><td align="left" rowspan="1" colspan="1">8.0</td><td align="left" rowspan="1" colspan="1">2,278</td><td align="left" rowspan="1" colspan="1">27.4</td><td align="left" rowspan="1" colspan="1">3,478</td><td align="left" rowspan="1" colspan="1">41.9</td><td align="left" rowspan="1" colspan="1">1,884</td><td align="left" rowspan="1" colspan="1">22.7</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="left" rowspan="1" colspan="1">1,487</td><td align="left" rowspan="1" colspan="1">5.6</td><td align="left" rowspan="1" colspan="1">11,966</td><td align="left" rowspan="1" colspan="1">44.7</td><td align="left" rowspan="1" colspan="1">10,893</td><td align="left" rowspan="1" colspan="1">40.7</td><td align="left" rowspan="1" colspan="1">2,422</td><td align="left" rowspan="1" colspan="1">9.0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="9" rowspan="1">Benzodiazepine</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">152</td><td align="left" rowspan="1" colspan="1">7.5</td><td align="left" rowspan="1" colspan="1">595</td><td align="left" rowspan="1" colspan="1">29.4</td><td align="left" rowspan="1" colspan="1">834</td><td align="left" rowspan="1" colspan="1">41.3</td><td align="left" rowspan="1" colspan="1">440</td><td align="left" rowspan="1" colspan="1">21.8</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="left" rowspan="1" colspan="1">1,998</td><td align="left" rowspan="1" colspan="1">6.0</td><td align="left" rowspan="1" colspan="1">13,649</td><td align="left" rowspan="1" colspan="1">41.3</td><td align="left" rowspan="1" colspan="1">13,537</td><td align="left" rowspan="1" colspan="1">41.0</td><td align="left" rowspan="1" colspan="1">3,866</td><td align="left" rowspan="1" colspan="1">11.7</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="9" rowspan="1">Polypharmacy (&#8805;6)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1,309</td><td align="left" rowspan="1" colspan="1">8.0</td><td align="left" rowspan="1" colspan="1">5,144</td><td align="left" rowspan="1" colspan="1">31.3</td><td align="left" rowspan="1" colspan="1">6,995</td><td align="left" rowspan="1" colspan="1">42.5</td><td align="left" rowspan="1" colspan="1">2,994</td><td align="left" rowspan="1" colspan="1">18.2</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="left" rowspan="1" colspan="1">841</td><td align="left" rowspan="1" colspan="1">4.5</td><td align="left" rowspan="1" colspan="1">9,100</td><td align="left" rowspan="1" colspan="1">48.8</td><td align="left" rowspan="1" colspan="1">7,376</td><td align="left" rowspan="1" colspan="1">39.6</td><td align="left" rowspan="1" colspan="1">1,312</td><td align="left" rowspan="1" colspan="1">7.0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="9" rowspan="1">Cancer stage</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Early stage</td><td align="left" rowspan="1" colspan="1">1,577</td><td align="left" rowspan="1" colspan="1">5.6</td><td align="left" rowspan="1" colspan="1">11,519</td><td align="left" rowspan="1" colspan="1">41.2</td><td align="left" rowspan="1" colspan="1">11,432</td><td align="left" rowspan="1" colspan="1">40.9</td><td align="left" rowspan="1" colspan="1">3,425</td><td align="left" rowspan="1" colspan="1">12.3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Advanced stage</td><td align="left" rowspan="1" colspan="1">440</td><td align="left" rowspan="1" colspan="1">9.0</td><td align="left" rowspan="1" colspan="1">1,714</td><td align="left" rowspan="1" colspan="1">35.3</td><td align="left" rowspan="1" colspan="1">2,081</td><td align="left" rowspan="1" colspan="1">42.8</td><td align="left" rowspan="1" colspan="1">627</td><td align="left" rowspan="1" colspan="1">12.9</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="9" rowspan="1">Type of cancer</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Breast</td><td align="left" rowspan="1" colspan="1">939</td><td align="left" rowspan="1" colspan="1">6.4</td><td align="left" rowspan="1" colspan="1">5,954</td><td align="left" rowspan="1" colspan="1">40.4</td><td align="left" rowspan="1" colspan="1">5,868</td><td align="left" rowspan="1" colspan="1">39.8</td><td align="left" rowspan="1" colspan="1">1,983</td><td align="left" rowspan="1" colspan="1">13.4</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Prostate</td><td align="left" rowspan="1" colspan="1">567</td><td align="left" rowspan="1" colspan="1">4.9</td><td align="left" rowspan="1" colspan="1">4,914</td><td align="left" rowspan="1" colspan="1">42.7</td><td align="left" rowspan="1" colspan="1">4,827</td><td align="left" rowspan="1" colspan="1">42.0</td><td align="left" rowspan="1" colspan="1">1,195</td><td align="left" rowspan="1" colspan="1">10.4</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Colorectal</td><td align="left" rowspan="1" colspan="1">422</td><td align="left" rowspan="1" colspan="1">7.1</td><td align="left" rowspan="1" colspan="1">2,342</td><td align="left" rowspan="1" colspan="1">39.3</td><td align="left" rowspan="1" colspan="1">2,427</td><td align="left" rowspan="1" colspan="1">40.7</td><td align="left" rowspan="1" colspan="1">773</td><td align="left" rowspan="1" colspan="1">13.0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-hodgkin lymphoma</td><td align="left" rowspan="1" colspan="1">222</td><td align="left" rowspan="1" colspan="1">7.7</td><td align="left" rowspan="1" colspan="1">1,034</td><td align="left" rowspan="1" colspan="1">35.8</td><td align="left" rowspan="1" colspan="1">1,249</td><td align="left" rowspan="1" colspan="1">43.2</td><td align="left" rowspan="1" colspan="1">355</td><td align="left" rowspan="1" colspan="1">12.3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="9" rowspan="1">Medicaid eligibility</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">334</td><td align="left" rowspan="1" colspan="1">7.8</td><td align="left" rowspan="1" colspan="1">1,419</td><td align="left" rowspan="1" colspan="1">33.1</td><td align="left" rowspan="1" colspan="1">1,594</td><td align="left" rowspan="1" colspan="1">37.2</td><td align="left" rowspan="1" colspan="1">937</td><td align="left" rowspan="1" colspan="1">21.9</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="left" rowspan="1" colspan="1">1,816</td><td align="left" rowspan="1" colspan="1">5.9</td><td align="left" rowspan="1" colspan="1">12,825</td><td align="left" rowspan="1" colspan="1">41.7</td><td align="left" rowspan="1" colspan="1">12,777</td><td align="left" rowspan="1" colspan="1">41.5</td><td align="left" rowspan="1" colspan="1">3,369</td><td align="left" rowspan="1" colspan="1">10.9</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="9" rowspan="1">Pain specialist visit</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Pain specialist visit</td><td align="left" rowspan="1" colspan="1">516</td><td align="left" rowspan="1" colspan="1">6.6</td><td align="left" rowspan="1" colspan="1">2133</td><td align="left" rowspan="1" colspan="1">27.5</td><td align="left" rowspan="1" colspan="1">3,892</td><td align="left" rowspan="1" colspan="1">50.1</td><td align="left" rowspan="1" colspan="1">1,229</td><td align="left" rowspan="1" colspan="1">15.8</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No pain specialist visit</td><td align="left" rowspan="1" colspan="1">1,634</td><td align="left" rowspan="1" colspan="1">6.0</td><td align="left" rowspan="1" colspan="1">12,111</td><td align="left" rowspan="1" colspan="1">44.4</td><td align="left" rowspan="1" colspan="1">10,479</td><td align="left" rowspan="1" colspan="1">38.4</td><td align="left" rowspan="1" colspan="1">3,077</td><td align="left" rowspan="1" colspan="1">11.3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="9" rowspan="1">Diagnosis year</td><td align="left" rowspan="1" colspan="1">0.0005</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;2009</td><td align="left" rowspan="1" colspan="1">367</td><td align="left" rowspan="1" colspan="1">5.9</td><td align="left" rowspan="1" colspan="1">2,625</td><td align="left" rowspan="1" colspan="1">41.9</td><td align="left" rowspan="1" colspan="1">2568</td><td align="left" rowspan="1" colspan="1">41.0</td><td align="left" rowspan="1" colspan="1">699</td><td align="left" rowspan="1" colspan="1">11.2</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;2010</td><td align="left" rowspan="1" colspan="1">456</td><td align="left" rowspan="1" colspan="1">6.9</td><td align="left" rowspan="1" colspan="1">2,696</td><td align="left" rowspan="1" colspan="1">40.9</td><td align="left" rowspan="1" colspan="1">2,693</td><td align="left" rowspan="1" colspan="1">40.9</td><td align="left" rowspan="1" colspan="1">744</td><td align="left" rowspan="1" colspan="1">11.3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;2011</td><td align="left" rowspan="1" colspan="1">430</td><td align="left" rowspan="1" colspan="1">6.2</td><td align="left" rowspan="1" colspan="1">2,735</td><td align="left" rowspan="1" colspan="1">39.7</td><td align="left" rowspan="1" colspan="1">2,811</td><td align="left" rowspan="1" colspan="1">40.8</td><td align="left" rowspan="1" colspan="1">916</td><td align="left" rowspan="1" colspan="1">13.3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;2012</td><td align="left" rowspan="1" colspan="1">418</td><td align="left" rowspan="1" colspan="1">5.8</td><td align="left" rowspan="1" colspan="1">2,892</td><td align="left" rowspan="1" colspan="1">40.0</td><td align="left" rowspan="1" colspan="1">2,979</td><td align="left" rowspan="1" colspan="1">41.2</td><td align="left" rowspan="1" colspan="1">935</td><td align="left" rowspan="1" colspan="1">12.9</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;2013</td><td align="left" rowspan="1" colspan="1">479</td><td align="left" rowspan="1" colspan="1">5.9</td><td align="left" rowspan="1" colspan="1">3,296</td><td align="left" rowspan="1" colspan="1">40.7</td><td align="left" rowspan="1" colspan="1">3,320</td><td align="left" rowspan="1" colspan="1">41.0</td><td align="left" rowspan="1" colspan="1">1,012</td><td align="left" rowspan="1" colspan="1">12.5</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="9" rowspan="1">Metropolitan status</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Metropolitan</td><td align="left" rowspan="1" colspan="1">1,739</td><td align="left" rowspan="1" colspan="1">5.9</td><td align="left" rowspan="1" colspan="1">12,209</td><td align="left" rowspan="1" colspan="1">41.3</td><td align="left" rowspan="1" colspan="1">12,164</td><td align="left" rowspan="1" colspan="1">41.2</td><td align="left" rowspan="1" colspan="1">3,416</td><td align="left" rowspan="1" colspan="1">11.6</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-metropolitan</td><td align="left" rowspan="1" colspan="1">363</td><td align="left" rowspan="1" colspan="1">7.5</td><td align="left" rowspan="1" colspan="1">1,788</td><td align="left" rowspan="1" colspan="1">37.1</td><td align="left" rowspan="1" colspan="1">1,929</td><td align="left" rowspan="1" colspan="1">40.0</td><td align="left" rowspan="1" colspan="1">743</td><td align="left" rowspan="1" colspan="1">15.4</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Rural</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">6.7</td><td align="left" rowspan="1" colspan="1">238</td><td align="left" rowspan="1" colspan="1">34.1</td><td align="left" rowspan="1" colspan="1">267</td><td align="left" rowspan="1" colspan="1">38.3</td><td align="left" rowspan="1" colspan="1">145</td><td align="left" rowspan="1" colspan="1">20.8</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="9" rowspan="1">Region</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Northeast</td><td align="left" rowspan="1" colspan="1">320</td><td align="left" rowspan="1" colspan="1">4.5</td><td align="left" rowspan="1" colspan="1">3,506</td><td align="left" rowspan="1" colspan="1">49.6</td><td align="left" rowspan="1" colspan="1">2,761</td><td align="left" rowspan="1" colspan="1">39.1</td><td align="left" rowspan="1" colspan="1">478</td><td align="left" rowspan="1" colspan="1">6.8</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;South</td><td align="left" rowspan="1" colspan="1">686</td><td align="left" rowspan="1" colspan="1">8.4</td><td align="left" rowspan="1" colspan="1">2,573</td><td align="left" rowspan="1" colspan="1">31.5</td><td align="left" rowspan="1" colspan="1">3,487</td><td align="left" rowspan="1" colspan="1">42.7</td><td align="left" rowspan="1" colspan="1">1,412</td><td align="left" rowspan="1" colspan="1">17.3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;North central</td><td align="left" rowspan="1" colspan="1">253</td><td align="left" rowspan="1" colspan="1">5.9</td><td align="left" rowspan="1" colspan="1">1,882</td><td align="left" rowspan="1" colspan="1">43.8</td><td align="left" rowspan="1" colspan="1">1,673</td><td align="left" rowspan="1" colspan="1">39.0</td><td align="left" rowspan="1" colspan="1">486</td><td align="left" rowspan="1" colspan="1">11.3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;West</td><td align="left" rowspan="1" colspan="1">891</td><td align="left" rowspan="1" colspan="1">5.7</td><td align="left" rowspan="1" colspan="1">6,283</td><td align="left" rowspan="1" colspan="1">40.4</td><td align="left" rowspan="1" colspan="1">6,450</td><td align="left" rowspan="1" colspan="1">41.5</td><td align="left" rowspan="1" colspan="1">1,930</td><td align="left" rowspan="1" colspan="1">12.4</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table frame="hsides" rules="groups"><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">SD</td><td align="center" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">SD</td><td align="center" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">SD</td><td align="center" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">SD</td></tr><tr><td align="left" rowspan="1" colspan="1">Age at cancer diagnosis</td><td align="char" char="." rowspan="1" colspan="1">75.61</td><td align="char" char="." rowspan="1" colspan="1">6.35</td><td align="char" char="." rowspan="1" colspan="1">76.37</td><td align="char" char="." rowspan="1" colspan="1">6.44</td><td align="char" char="." rowspan="1" colspan="1">75.77</td><td align="char" char="." rowspan="1" colspan="1">6.19</td><td align="char" char="." rowspan="1" colspan="1">75.35</td><td align="char" char="." rowspan="1" colspan="1">6.15</td></tr><tr><td align="left" rowspan="1" colspan="1">Zip Code Level Median Income</td><td align="char" char="." rowspan="1" colspan="1">39,699.50</td><td align="char" char="." rowspan="1" colspan="1">23,344.20</td><td align="char" char="." rowspan="1" colspan="1">43,326.60</td><td align="char" char="." rowspan="1" colspan="1">25,804.21</td><td align="char" char="." rowspan="1" colspan="1">42,274.19</td><td align="char" char="." rowspan="1" colspan="1">25,129.04</td><td align="char" char="." rowspan="1" colspan="1">37,781.15</td><td align="char" char="." rowspan="1" colspan="1">22,307.44</td></tr><tr><td align="left" rowspan="1" colspan="1">Education (% less than HS education)</td><td align="char" char="." rowspan="1" colspan="1">25.45</td><td align="char" char="." rowspan="1" colspan="1">16.74</td><td align="char" char="." rowspan="1" colspan="1">23.29</td><td align="char" char="." rowspan="1" colspan="1">16.59</td><td align="char" char="." rowspan="1" colspan="1">23.92</td><td align="char" char="." rowspan="1" colspan="1">16.71</td><td align="char" char="." rowspan="1" colspan="1">26.84</td><td align="char" char="." rowspan="1" colspan="1">16.91</td></tr><tr><td align="left" rowspan="1" colspan="1">Poverty percentage</td><td align="char" char="." rowspan="1" colspan="1">15.44</td><td align="char" char="." rowspan="1" colspan="1">12.67</td><td align="char" char="." rowspan="1" colspan="1">13.87</td><td align="char" char="." rowspan="1" colspan="1">12.23</td><td align="char" char="." rowspan="1" colspan="1">14.35</td><td align="char" char="." rowspan="1" colspan="1">12.41</td><td align="char" char="." rowspan="1" colspan="1">16.39</td><td align="char" char="." rowspan="1" colspan="1">12.85</td></tr><tr><td align="left" rowspan="1" colspan="1">Fragmented care index (x 10)</td><td align="char" char="." rowspan="1" colspan="1">7.30</td><td align="char" char="." rowspan="1" colspan="1">2.56</td><td align="char" char="." rowspan="1" colspan="1">7.24</td><td align="char" char="." rowspan="1" colspan="1">2.38</td><td align="char" char="." rowspan="1" colspan="1">7.38</td><td align="char" char="." rowspan="1" colspan="1">2.52</td><td align="char" char="." rowspan="1" colspan="1">7.23</td><td align="char" char="." rowspan="1" colspan="1">2.63</td></tr><tr><td align="left" rowspan="1" colspan="1">% medicare advantage penetration</td><td align="char" char="." rowspan="1" colspan="1">24.41</td><td align="char" char="." rowspan="1" colspan="1">12.82</td><td align="char" char="." rowspan="1" colspan="1">24.83</td><td align="char" char="." rowspan="1" colspan="1">12.84</td><td align="char" char="." rowspan="1" colspan="1">25.22</td><td align="char" char="." rowspan="1" colspan="1">12.82</td><td align="char" char="." rowspan="1" colspan="1">25.06</td><td align="char" char="." rowspan="1" colspan="1">12.93</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Note: Based on 35,071 adults with NCPCs 67 years or older, diagnosed with incident primary breast, prostate, colorectal cancers, and NHL between 2009 and 2015, continuously enrolled in fee-for-service medicare parts a and B for 24-month, and continuously enrolled in medicare part D for 12 months before and 24&#160;months after cancer diagnosis. Group differences by opioid use categories were tested with chi-square test.</p></fn><fn><p>Abbreviations: NHL: Non-hodgkin lymphoma, Wid/Sep/Div: Widow/Separate/Divorce, HS: High School, SD: Standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="table3-10732748241290769" orientation="portrait"><label>Table 3.</label><caption><p>Unadjusted Odds Ratios (AOR) and 95% Confidence Intervals (CI) from Multivariable Logistic Regressions on Opioid Trajectory Groups with &#8220;Low Use&#8221; as Reference Group Among Older Medicare Beneficiaries with any NCPC and Breast, Colorectal, Prostate, or NHL Linked Surveillance, Epidemiology, and End Results (SEER) and Medicare, 2007-2015.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="table3-10732748241290769" position="float" orientation="portrait" xlink:href="10.1177_10732748241290769-table3.jpg"/><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="2" colspan="1"/><th align="center" colspan="3" rowspan="1">Increase-Decrease Use</th><th align="center" colspan="3" rowspan="1">Short-term Use after Cancer Diagnosis</th><th align="center" colspan="3" rowspan="1">Persistent Use</th></tr><tr><th align="left" rowspan="1" colspan="1">UOR</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">Sig</th><th align="center" rowspan="1" colspan="1">UOR</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">Sig</th><th align="center" rowspan="1" colspan="1">UOR</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">Sig</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="10" rowspan="1">Sex</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Female (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Male</td><td align="left" rowspan="1" colspan="1">0.75</td><td align="left" rowspan="1" colspan="1">[0.68, 0.83]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">[0.95, 1.05]</td><td align="left" rowspan="1" colspan="1">0.9814</td><td align="left" rowspan="1" colspan="1">0.75</td><td align="left" rowspan="1" colspan="1">[0.70, 0.81]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" colspan="10" rowspan="1">Age</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;67-74 (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&gt;=75</td><td align="left" rowspan="1" colspan="1">0.96</td><td align="left" rowspan="1" colspan="1">[0.88, 1.05]</td><td align="left" rowspan="1" colspan="1">0.3864</td><td align="left" rowspan="1" colspan="1">1.16</td><td align="left" rowspan="1" colspan="1">[1.10, 1.21]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">0.91</td><td align="left" rowspan="1" colspan="1">[0.85, 0.97]</td><td align="left" rowspan="1" colspan="1">0.0050</td></tr><tr><td align="left" colspan="10" rowspan="1">Race and ethnicity</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-hispanic white (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-hispanic black</td><td align="left" rowspan="1" colspan="1">1.48</td><td align="left" rowspan="1" colspan="1">[1.28, 1.71]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">0.88</td><td align="left" rowspan="1" colspan="1">[0.80, 0.96]</td><td align="left" rowspan="1" colspan="1">0.0039</td><td align="left" rowspan="1" colspan="1">1.90</td><td align="left" rowspan="1" colspan="1">[1.70, 2.11]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Latino/hispanic</td><td align="left" rowspan="1" colspan="1">1.08</td><td align="left" rowspan="1" colspan="1">[0.91, 1.28]</td><td align="left" rowspan="1" colspan="1">0.3727</td><td align="left" rowspan="1" colspan="1">0.81</td><td align="left" rowspan="1" colspan="1">[0.74, 0.89]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">1.06</td><td align="left" rowspan="1" colspan="1">[0.93, 1.21]</td><td align="left" rowspan="1" colspan="1">0.3464</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Other races</td><td align="left" rowspan="1" colspan="1">0.68</td><td align="left" rowspan="1" colspan="1">[0.53, 0.87]</td><td align="left" rowspan="1" colspan="1">0.0025</td><td align="left" rowspan="1" colspan="1">1.33</td><td align="left" rowspan="1" colspan="1">[1.21, 1.47]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">0.51</td><td align="left" rowspan="1" colspan="1">[0.41, 0.63]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" colspan="10" rowspan="1">Cancer type</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Breast</td><td align="left" rowspan="1" colspan="1">0.87</td><td align="left" rowspan="1" colspan="1">[0.74, 1.02]</td><td align="left" rowspan="1" colspan="1">0.0904</td><td align="left" rowspan="1" colspan="1">1.26</td><td align="left" rowspan="1" colspan="1">[1.15, 1.38]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">1.16</td><td align="left" rowspan="1" colspan="1">[1.02, 1.33]</td><td align="left" rowspan="1" colspan="1">0.0265</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Colorectal</td><td align="left" rowspan="1" colspan="1">0.63</td><td align="left" rowspan="1" colspan="1">[0.53, 0.75]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">1.25</td><td align="left" rowspan="1" colspan="1">[1.13, 1.37]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">0.85</td><td align="left" rowspan="1" colspan="1">[0.74, 0.98]</td><td align="left" rowspan="1" colspan="1">0.0240</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Prostate</td><td align="left" rowspan="1" colspan="1">0.95</td><td align="left" rowspan="1" colspan="1">[0.80, 1.14]</td><td align="left" rowspan="1" colspan="1">0.6122</td><td align="left" rowspan="1" colspan="1">1.20</td><td align="left" rowspan="1" colspan="1">[1.08, 1.33]</td><td align="left" rowspan="1" colspan="1">0.0007</td><td align="left" rowspan="1" colspan="1">1.10</td><td align="left" rowspan="1" colspan="1">[0.95, 1.28]</td><td align="left" rowspan="1" colspan="1">0.1983</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;NHL (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" rowspan="1">Metropolitan status</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Metro (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Nonmetro</td><td align="left" rowspan="1" colspan="1">1.31</td><td align="left" rowspan="1" colspan="1">[1.16, 1.49]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">0.93</td><td align="left" rowspan="1" colspan="1">[0.87, 1.00]</td><td align="left" rowspan="1" colspan="1">0.0616</td><td align="left" rowspan="1" colspan="1">1.35</td><td align="left" rowspan="1" colspan="1">[1.22, 1.48]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Rural</td><td align="left" rowspan="1" colspan="1">1.29</td><td align="left" rowspan="1" colspan="1">[0.94, 1.78]</td><td align="left" rowspan="1" colspan="1">0.1167</td><td align="left" rowspan="1" colspan="1">0.89</td><td align="left" rowspan="1" colspan="1">[0.74, 1.07]</td><td align="left" rowspan="1" colspan="1">0.2236</td><td align="left" rowspan="1" colspan="1">1.90</td><td align="left" rowspan="1" colspan="1">[1.54, 2.35]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" colspan="10" rowspan="1">Marital status</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Married (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Wid/sep/div</td><td align="left" rowspan="1" colspan="1">1.25</td><td align="left" rowspan="1" colspan="1">[1.13, 1.39]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">0.96</td><td align="left" rowspan="1" colspan="1">[0.91, 1.02]</td><td align="left" rowspan="1" colspan="1">0.1591</td><td align="left" rowspan="1" colspan="1">1.74</td><td align="left" rowspan="1" colspan="1">[1.61, 1.88]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Never married</td><td align="left" rowspan="1" colspan="1">1.32</td><td align="left" rowspan="1" colspan="1">[1.12, 1.56]</td><td align="left" rowspan="1" colspan="1">0.0012</td><td align="left" rowspan="1" colspan="1">1.03</td><td align="left" rowspan="1" colspan="1">[0.94, 1.13]</td><td align="left" rowspan="1" colspan="1">0.4851</td><td align="left" rowspan="1" colspan="1">1.58</td><td align="left" rowspan="1" colspan="1">[1.39, 1.80]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" colspan="10" rowspan="1">Region</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;South</td><td align="left" rowspan="1" colspan="1">1.75</td><td align="left" rowspan="1" colspan="1">[1.51, 2.02]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">0.58</td><td align="left" rowspan="1" colspan="1">[0.54, 0.62]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">2.34</td><td align="left" rowspan="1" colspan="1">[2.08, 2.63]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;North central</td><td align="left" rowspan="1" colspan="1">1.35</td><td align="left" rowspan="1" colspan="1">[1.12, 1.61]</td><td align="left" rowspan="1" colspan="1">0.0012</td><td align="left" rowspan="1" colspan="1">0.88</td><td align="left" rowspan="1" colspan="1">[0.81, 0.96]</td><td align="left" rowspan="1" colspan="1">0.0029</td><td align="left" rowspan="1" colspan="1">1.65</td><td align="left" rowspan="1" colspan="1">[1.43, 1.90]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;West</td><td align="left" rowspan="1" colspan="1">1.23</td><td align="left" rowspan="1" colspan="1">[1.06, 1.41]</td><td align="left" rowspan="1" colspan="1">0.0049</td><td align="left" rowspan="1" colspan="1">0.76</td><td align="left" rowspan="1" colspan="1">[0.71, 0.81]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">1.72</td><td align="left" rowspan="1" colspan="1">[1.54, 1.93]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Northeast (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" rowspan="1">Medicaid eligibility</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1.21</td><td align="left" rowspan="1" colspan="1">[1.06, 1.37]</td><td align="left" rowspan="1" colspan="1">0.0037</td><td align="left" rowspan="1" colspan="1">0.77</td><td align="left" rowspan="1" colspan="1">[0.71, 0.83]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">2.00</td><td align="left" rowspan="1" colspan="1">[1.83, 2.19]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" rowspan="1">Pain specialist visit</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">0.85</td><td align="left" rowspan="1" colspan="1">[0.76, 0.94]</td><td align="left" rowspan="1" colspan="1">0.0027</td><td align="left" rowspan="1" colspan="1">0.47</td><td align="left" rowspan="1" colspan="1">[0.45, 0.50]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">1.08</td><td align="left" rowspan="1" colspan="1">[0.99, 1.16]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" rowspan="1">Substance abuse</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1.52</td><td align="left" rowspan="1" colspan="1">[1.26, 1.84]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">0.59</td><td align="left" rowspan="1" colspan="1">[0.52, 0.67]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">2.76</td><td align="left" rowspan="1" colspan="1">[2.44, 3.12]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" rowspan="1">Depression</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1.35</td><td align="left" rowspan="1" colspan="1">[1.18, 1.54]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">0.62</td><td align="left" rowspan="1" colspan="1">[0.57, 0.67]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">2.02</td><td align="left" rowspan="1" colspan="1">[1.84, 2.21]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" rowspan="1">Anxiety</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1.30</td><td align="left" rowspan="1" colspan="1">[1.12, 1.51]</td><td align="left" rowspan="1" colspan="1">0.0005</td><td align="left" rowspan="1" colspan="1">0.68</td><td align="left" rowspan="1" colspan="1">[0.62, 0.74]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">2.09</td><td align="left" rowspan="1" colspan="1">[1.89, 2.31]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" rowspan="1">Comorbidities (&gt;=2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1.15</td><td align="left" rowspan="1" colspan="1">[1.02, 1.30]</td><td align="left" rowspan="1" colspan="1">0.0224</td><td align="left" rowspan="1" colspan="1">0.87</td><td align="left" rowspan="1" colspan="1">[0.82, 0.92]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">1.16</td><td align="left" rowspan="1" colspan="1">[1.06, 1.27]</td><td align="left" rowspan="1" colspan="1">0.0014</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" rowspan="1">Polypharmacy</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1.67</td><td align="left" rowspan="1" colspan="1">[1.52, 1.83]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">0.60</td><td align="left" rowspan="1" colspan="1">[0.57, 0.63]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">2.45</td><td align="left" rowspan="1" colspan="1">[2.27, 2.64]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" rowspan="1">Prescription NSAIDs</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1.30</td><td align="left" rowspan="1" colspan="1">[1.18, 1.43]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">0.52</td><td align="left" rowspan="1" colspan="1">[0.49, 0.55]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">1.49</td><td align="left" rowspan="1" colspan="1">[1.38, 1.60]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" rowspan="1">Steroids</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1.14</td><td align="left" rowspan="1" colspan="1">[1.04, 1.26]</td><td align="left" rowspan="1" colspan="1">0.0049</td><td align="left" rowspan="1" colspan="1">0.70</td><td align="left" rowspan="1" colspan="1">[0.67, 0.73]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">1.33</td><td align="left" rowspan="1" colspan="1">[1.24, 1.43]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" rowspan="1">Antidepressants</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1.39</td><td align="left" rowspan="1" colspan="1">[1.25, 1.54]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">0.59</td><td align="left" rowspan="1" colspan="1">[0.56, 0.63]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">2.48</td><td align="left" rowspan="1" colspan="1">[2.30, 2.66]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" rowspan="1">Benzodiazepine</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1.21</td><td align="left" rowspan="1" colspan="1">[1.01, 1.46]</td><td align="left" rowspan="1" colspan="1">0.0405</td><td align="left" rowspan="1" colspan="1">0.72</td><td align="left" rowspan="1" colspan="1">[0.64, 0.80]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">1.86</td><td align="left" rowspan="1" colspan="1">[1.64, 2.11]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Fragmented care index (x 10)</td><td align="left" rowspan="1" colspan="1">0.99</td><td align="left" rowspan="1" colspan="1">[0.97, 1.01]</td><td align="left" rowspan="1" colspan="1">0.1501</td><td align="left" rowspan="1" colspan="1">0.98</td><td align="left" rowspan="1" colspan="1">[0.97, 0.99]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">0.98</td><td align="left" rowspan="1" colspan="1">[0.96, 0.99]</td><td align="left" rowspan="1" colspan="1">0.0016</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Note: Based on 35,071 adults with NCPCs (67 years at cancer diagnosis) or older, diagnosed with incident primary breast, prostate, colorectal cancers, and NHL between 2009 and 2015, continuously enrolled in Fee-for-Service Medicare Parts A and B for 24-month, and continuously enrolled in Medicare part D for 12 months before and 24 months after cancer diagnosis.</p></fn><fn><p>Abbreviations: NHL: Non-Hodgkin Lymphoma, Wid/Sep/Div: Widow/Separate/Divorce.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="table4-10732748241290769" orientation="portrait"><label>Table 4.</label><caption><p>Fully-Adjusted Odds Ratios (AOR) and 95% Confidence Intervals (CI) from Multivariable Logistic Regressions on Opioid Trajectory Groups with &#8220;Low Use&#8221; as Reference Group among Older Medicare Beneficiaries with any NCPC and Breast, Colorectal, Prostate, and NHL Linked Surveillance, Epidemiology, and End Results (SEER) and Medicare, 2007-2015.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="table4-10732748241290769" position="float" orientation="portrait" xlink:href="10.1177_10732748241290769-table4.jpg"/><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="2" colspan="1"/><th align="center" colspan="3" rowspan="1">Increase-Decrease Use</th><th align="center" colspan="3" rowspan="1">Short-Term Use after Cancer Diagnosis</th><th align="center" colspan="3" rowspan="1">Persistent Use</th></tr><tr><th align="left" rowspan="1" colspan="1">AOR</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">Sig</th><th align="center" rowspan="1" colspan="1">AOR</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">Sig</th><th align="center" rowspan="1" colspan="1">AOR</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">Sig</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="10" rowspan="1">Sex</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Female (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Male</td><td align="left" rowspan="1" colspan="1">0.75</td><td align="left" rowspan="1" colspan="1">[0.67, 0.85]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">0.99</td><td align="left" rowspan="1" colspan="1">[0.93, 1.05]</td><td align="left" rowspan="1" colspan="1">0.6354</td><td align="left" rowspan="1" colspan="1">0.92</td><td align="left" rowspan="1" colspan="1">[0.84, 1.01]</td><td align="left" rowspan="1" colspan="1">0.0723</td></tr><tr><td align="left" colspan="10" rowspan="1">Race and ethnicity</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-hispanic white (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-hispanic black</td><td align="left" rowspan="1" colspan="1">1.24</td><td align="left" rowspan="1" colspan="1">[1.04, 1.49]</td><td align="left" rowspan="1" colspan="1">0.0190</td><td align="left" rowspan="1" colspan="1">0.91</td><td align="left" rowspan="1" colspan="1">[0.82, 1.02]</td><td align="left" rowspan="1" colspan="1">0.1080</td><td align="left" rowspan="1" colspan="1">1.69</td><td align="left" rowspan="1" colspan="1">[1.48, 1.93]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Latino/hispanic</td><td align="left" rowspan="1" colspan="1">1.07</td><td align="left" rowspan="1" colspan="1">[0.87, 1.30]</td><td align="left" rowspan="1" colspan="1">0.5351</td><td align="left" rowspan="1" colspan="1">0.85</td><td align="left" rowspan="1" colspan="1">[0.76, 0.96]</td><td align="left" rowspan="1" colspan="1">0.0059</td><td align="left" rowspan="1" colspan="1">0.86</td><td align="left" rowspan="1" colspan="1">[0.73, 1.01]</td><td align="left" rowspan="1" colspan="1">0.0654</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Other races</td><td align="left" rowspan="1" colspan="1">0.65</td><td align="left" rowspan="1" colspan="1">[0.49, 0.87]</td><td align="left" rowspan="1" colspan="1">0.0039</td><td align="left" rowspan="1" colspan="1">1.50</td><td align="left" rowspan="1" colspan="1">[1.32, 1.69]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">0.45</td><td align="left" rowspan="1" colspan="1">[0.35, 0.57]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" colspan="10" rowspan="1">Metropolitan status</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Metro (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-metro</td><td align="left" rowspan="1" colspan="1">1.10</td><td align="left" rowspan="1" colspan="1">[0.93, 1.30]</td><td align="left" rowspan="1" colspan="1">0.2579</td><td align="left" rowspan="1" colspan="1">1.06</td><td align="left" rowspan="1" colspan="1">[0.96, 1.17]</td><td align="left" rowspan="1" colspan="1">0.2486</td><td align="left" rowspan="1" colspan="1">1.07</td><td align="left" rowspan="1" colspan="1">[0.94, 1.22]</td><td align="left" rowspan="1" colspan="1">0.3076</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Rural</td><td align="left" rowspan="1" colspan="1">1.07</td><td align="left" rowspan="1" colspan="1">[0.74, 1.54]</td><td align="left" rowspan="1" colspan="1">0.7200</td><td align="left" rowspan="1" colspan="1">1.08</td><td align="left" rowspan="1" colspan="1">[0.87, 1.35]</td><td align="left" rowspan="1" colspan="1">0.4710</td><td align="left" rowspan="1" colspan="1">1.49</td><td align="left" rowspan="1" colspan="1">[1.15, 1.94]</td><td align="left" rowspan="1" colspan="1">0.0027</td></tr><tr><td align="left" colspan="10" rowspan="1">Marital status</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Married (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Wid/Sep/Div</td><td align="left" rowspan="1" colspan="1">1.06</td><td align="left" rowspan="1" colspan="1">[0.93, 1.21]</td><td align="left" rowspan="1" colspan="1">0.3616</td><td align="left" rowspan="1" colspan="1">0.95</td><td align="left" rowspan="1" colspan="1">[0.89, 1.02]</td><td align="left" rowspan="1" colspan="1">0.1640</td><td align="left" rowspan="1" colspan="1">1.41</td><td align="left" rowspan="1" colspan="1">[1.28, 1.56]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Never married</td><td align="left" rowspan="1" colspan="1">1.16</td><td align="left" rowspan="1" colspan="1">[0.95, 1.40]</td><td align="left" rowspan="1" colspan="1">0.1399</td><td align="left" rowspan="1" colspan="1">1.01</td><td align="left" rowspan="1" colspan="1">[0.91, 1.12]</td><td align="left" rowspan="1" colspan="1">0.8513</td><td align="left" rowspan="1" colspan="1">1.18</td><td align="left" rowspan="1" colspan="1">[1.02, 1.38]</td><td align="left" rowspan="1" colspan="1">0.0290</td></tr><tr><td align="left" colspan="10" rowspan="1">Region</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Northeast (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;South</td><td align="left" rowspan="1" colspan="1">1.59</td><td align="left" rowspan="1" colspan="1">[1.32, 1.91]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">0.55</td><td align="left" rowspan="1" colspan="1">[0.50, 0.60]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">1.82</td><td align="left" rowspan="1" colspan="1">[1.57, 2.11]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;North central</td><td align="left" rowspan="1" colspan="1">1.41</td><td align="left" rowspan="1" colspan="1">[1.15, 1.75]</td><td align="left" rowspan="1" colspan="1">0.0012</td><td align="left" rowspan="1" colspan="1">0.74</td><td align="left" rowspan="1" colspan="1">[0.67, 0.82]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">1.63</td><td align="left" rowspan="1" colspan="1">[1.37, 1.93]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;West</td><td align="left" rowspan="1" colspan="1">1.42</td><td align="left" rowspan="1" colspan="1">[1.18, 1.71]</td><td align="left" rowspan="1" colspan="1">0.0003</td><td align="left" rowspan="1" colspan="1">0.66</td><td align="left" rowspan="1" colspan="1">[0.60, 0.72]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">2.05</td><td align="left" rowspan="1" colspan="1">[1.77, 2.39]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" colspan="10" rowspan="1">Medicaid eligibility</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1.26</td><td align="left" rowspan="1" colspan="1">[1.08, 1.49]</td><td align="left" rowspan="1" colspan="1">0.0038</td><td align="left" rowspan="1" colspan="1">1.08</td><td align="left" rowspan="1" colspan="1">[0.97, 1.20]</td><td align="left" rowspan="1" colspan="1">0.0921</td><td align="left" rowspan="1" colspan="1">1.73</td><td align="left" rowspan="1" colspan="1">[1.54, 1.94]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" rowspan="1">Pain specialist visit</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">0.91</td><td align="left" rowspan="1" colspan="1">[0.80, 1.04]</td><td align="left" rowspan="1" colspan="1">0.1569</td><td align="left" rowspan="1" colspan="1">0.47</td><td align="left" rowspan="1" colspan="1">[0.44, 0.51]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">1.16</td><td align="left" rowspan="1" colspan="1">[1.05,1.28]</td><td align="left" rowspan="1" colspan="1">0.0022</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" rowspan="1">Substance abuse</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1.46</td><td align="left" rowspan="1" colspan="1">[1.19, 1.81]</td><td align="left" rowspan="1" colspan="1">0.0004</td><td align="left" rowspan="1" colspan="1">0.71</td><td align="left" rowspan="1" colspan="1">[0.62, 0.83]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">2.20</td><td align="left" rowspan="1" colspan="1">[1.91, 2.55]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" rowspan="1">Depression</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1.04</td><td align="left" rowspan="1" colspan="1">[0.87, 1.23]</td><td align="left" rowspan="1" colspan="1">0.6730</td><td align="left" rowspan="1" colspan="1">0.87</td><td align="left" rowspan="1" colspan="1">[0.78, 0.97]</td><td align="left" rowspan="1" colspan="1">0.0120</td><td align="left" rowspan="1" colspan="1">1.06</td><td align="left" rowspan="1" colspan="1">[0.94, 1.20]</td><td align="left" rowspan="1" colspan="1">0.3481</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" rowspan="1">Anxiety</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1.02</td><td align="left" rowspan="1" colspan="1">[0.85, 1.22]</td><td align="left" rowspan="1" colspan="1">0.8229</td><td align="left" rowspan="1" colspan="1">0.89</td><td align="left" rowspan="1" colspan="1">[0.80, 0.99]</td><td align="left" rowspan="1" colspan="1">0.0401</td><td align="left" rowspan="1" colspan="1">1.33</td><td align="left" rowspan="1" colspan="1">[1.18, 1.51]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" rowspan="1">Comorbidities (&gt;=2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1.02</td><td align="left" rowspan="1" colspan="1">[0.87, 1.20]</td><td align="left" rowspan="1" colspan="1">0.7861</td><td align="left" rowspan="1" colspan="1">0.96</td><td align="left" rowspan="1" colspan="1">[0.89, 1.04]</td><td align="left" rowspan="1" colspan="1">0.3645</td><td align="left" rowspan="1" colspan="1">0.94</td><td align="left" rowspan="1" colspan="1">[0.83, 1.07]</td><td align="left" rowspan="1" colspan="1">0.3580</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" rowspan="1">Polypharmacy</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1.48</td><td align="left" rowspan="1" colspan="1">[1.31, 1.66]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">0.72</td><td align="left" rowspan="1" colspan="1">[0.68, 0.77]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">1.84</td><td align="left" rowspan="1" colspan="1">[1.68, 2.02]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" rowspan="1">Prescription NSAIDs</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1.17</td><td align="left" rowspan="1" colspan="1">[1.05, 1.31]</td><td align="left" rowspan="1" colspan="1">0.0047</td><td align="left" rowspan="1" colspan="1">0.58</td><td align="left" rowspan="1" colspan="1">[0.54, 0.62]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">1.20</td><td align="left" rowspan="1" colspan="1">[1.10, 1.30]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" rowspan="1">Steroids</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1.07</td><td align="left" rowspan="1" colspan="1">[0.96, 1.19]</td><td align="left" rowspan="1" colspan="1">0.2507</td><td align="left" rowspan="1" colspan="1">0.86</td><td align="left" rowspan="1" colspan="1">[0.81, 0.91]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">1.15</td><td align="left" rowspan="1" colspan="1">[1.06, 1.25]</td><td align="left" rowspan="1" colspan="1">0.0013</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" rowspan="1">Antidepressants</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1.13</td><td align="left" rowspan="1" colspan="1">[0.99, 1.30]</td><td align="left" rowspan="1" colspan="1">0.0658</td><td align="left" rowspan="1" colspan="1">0.77</td><td align="left" rowspan="1" colspan="1">[0.71, 0.84]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">1.79</td><td align="left" rowspan="1" colspan="1">[1.62, 1.97]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="10" rowspan="1">Benzodiazepine</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="left" rowspan="1" colspan="1">1.01</td><td align="left" rowspan="1" colspan="1">[0.82, 1.25]</td><td align="left" rowspan="1" colspan="1">0.9115</td><td align="left" rowspan="1" colspan="1">0.89</td><td align="left" rowspan="1" colspan="1">[0.79, 1.01]</td><td align="left" rowspan="1" colspan="1">0.0824</td><td align="left" rowspan="1" colspan="1">1.40</td><td align="left" rowspan="1" colspan="1">[1.22, 1.62]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No (ref)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age at cancer diagnosis (x5)</td><td align="left" rowspan="1" colspan="1">0.97</td><td align="left" rowspan="1" colspan="1">[0.96, 0.98]</td><td align="left" rowspan="1" colspan="1">0.1709</td><td align="left" rowspan="1" colspan="1">1.06</td><td align="left" rowspan="1" colspan="1">[1.05, 1.07]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td><td align="left" rowspan="1" colspan="1">0.94</td><td align="left" rowspan="1" colspan="1">[0.93, 0.95]</td><td align="left" rowspan="1" colspan="1">0.0002</td></tr><tr><td align="left" rowspan="1" colspan="1">Zipcode-level percentage below poverty line</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">[0.99, 1.00]</td><td align="left" rowspan="1" colspan="1">0.5456</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">[1.00, 1.00]</td><td align="left" rowspan="1" colspan="1">0.9087</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">[1.00, 1.01]</td><td align="left" rowspan="1" colspan="1">0.5105</td></tr><tr><td align="left" rowspan="1" colspan="1">Zip code level education (% less than HS education)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">[1.00, 1.01]</td><td align="left" rowspan="1" colspan="1">0.3860</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">[1.00, 1.00]</td><td align="left" rowspan="1" colspan="1">0.5861</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">[1.00, 1.01]</td><td align="left" rowspan="1" colspan="1">0.0075</td></tr><tr><td align="left" rowspan="1" colspan="1">Fragmented care index (x 10)</td><td align="left" rowspan="1" colspan="1">0.98</td><td align="left" rowspan="1" colspan="1">[0.95, 1.00]</td><td align="left" rowspan="1" colspan="1">0.0567</td><td align="left" rowspan="1" colspan="1">1.02</td><td align="left" rowspan="1" colspan="1">[1.01, 1.04]</td><td align="left" rowspan="1" colspan="1">0.0011</td><td align="left" rowspan="1" colspan="1">0.95</td><td align="left" rowspan="1" colspan="1">[0.93, 0.97]</td><td align="left" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Medicare advantage penetration (x5)</td><td align="left" rowspan="1" colspan="1">0.96</td><td align="left" rowspan="1" colspan="1">[0.96, 0.97]</td><td align="left" rowspan="1" colspan="1">0.0104</td><td align="left" rowspan="1" colspan="1">1.01</td><td align="left" rowspan="1" colspan="1">[1.00, 1.01]</td><td align="left" rowspan="1" colspan="1">0.1431</td><td align="left" rowspan="1" colspan="1">0.96</td><td align="left" rowspan="1" colspan="1">[0.95, 0.97]</td><td align="left" rowspan="1" colspan="1">0.0004</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Note: Based on 35,071 adults with NCPCs 67 years or older, diagnosed with incident primary breast, prostate, colorectal cancers, and NHL between 2009 and 2015, continuously enrolled in Fee-for-Service Medicare part A and B for 24 months, and continuously enrolled in Medicare part D for 12 months before cancer diagnosis. Group differences by opioid use group trajectory were tested with Chi-Square test.</p></fn><fn><p>Abbreviations: NHL: Non-Hodgkin Lymphoma, Wid/Sep/Div: Widow/Separate/Divorce.</p></fn></table-wrap-foot></table-wrap></p><p>The fully adjusted multivariable multinomial logistic regression (MLR) revealed that the group membership differed by some SDoH, mental health, pain medication, and health care use factors. For example, Non-Hispanic Black (AOR = 1.69; 95%CI = 1.48, 1.93, compared to Non-Hispanic White) and rural residents (AOR = 1.49; 95%CI = 1.15, 1.94, compared to metropolitan) were more likely to be in &#8220;persistent use.&#8221; Older adults with anxiety (AOR = 1.33; 95%CI = 1.18, 1.51)) and pain medications (NSAIDs (AOR = 1.20; 95%CI = 1.10, 1.30, <italic toggle="yes">P</italic> &lt; 0.0001), steroids (AOR = 1.15; 95%CI = 1.06, 1.25, <italic toggle="yes">P</italic> = 0.0013), polypharmacy (AOR = 1.84; 95%CI = 1.68, 2.02, <italic toggle="yes">P</italic> &lt; 0.0001)) were among some of the factors associated with membership in the &#8220;persistent use.&#8221; Group membership in the &#8220;persistent use&#8221; was less likely among those with fragmented care (AOR = 0.95, 95%CI = 0.93, 0.97, <italic toggle="yes">P</italic> &lt; 0.0001) and those living in higher Medicare advantage penetration counties (AOR = 0.96; 95%CI = 0.95, 0.97, <italic toggle="yes">P</italic> = 0.0004).</p><p>On the other hand, some SDoH, anxiety and pain medications, and health care use were associated with lower odds of short-term opioid use after cancer diagnosis. For example, Latino/Hispanics (AOR = 0.85; 95%CI = 0.76, 0.96, <italic toggle="yes">P</italic> = 0.0059, compared to Non-Hispanic Whites) were less likely to have short-term opioid use after cancer diagnosis. Individuals with anxiety (AOR = 0.89, 95%CI = 0.80, 0.99, <italic toggle="yes">P</italic> = 0.0401) and pain medication use (NSAIDs (AOR = 0.58; 95%CI = 0.54, 0.62, <italic toggle="yes">P</italic> &lt; 0.0001), steroids (AOR = 0.86; 95%CI = 0.81, 0.91, <italic toggle="yes">P</italic> &lt; 0.0001) were less likely to be in &#8220;short-term use after cancer diagnosis&#8221; group. Group membership in the &#8220;short-term use after cancer diagnosis&#8221; was more likely among those with fragmented care (AOR = 1.02, 95%CI = 1.01, 1.04, <italic toggle="yes">P</italic> = 0.0011).</p></sec></sec><sec sec-type="discussion" id="sec23-10732748241290769"><title>Discussion</title><p>This study examined distinctive trajectories of prescription opioid use over time (before and after cancer) and factors associated with the trajectories among older NCPC adults with incident breast, colorectal, non-Hodgkin&#8217;s lymphoma, and prostate cancers. This study identified trajectory models that further elucidated our understanding of the pattern of older adults&#8217; opioid use before and after cancer. In this study cohort, we identified four distinct patterns of opioid use. We found that 40.6% of older adults with NCPC and incident cancer used opioids for a short-term, in accordance with the guidelines that suggest discontinuing opioid use after the acute treatment phase. We also found that 41.0% had a low probability of opioid use over time. However, 12.4% belonged to the &#8220;persistent use&#8221; group. Taken together, these findings suggest that there is heterogeneity in opioid use patterns and an overwhelming majority of older adults with NCPC and cancer may be prescribed opioids consistent with the guidelines. In addition, we also observed that in all trajectory groups, opioid use peaked during the 90 days after a cancer diagnosis. The high probability of opioid use during the acute phase of cancer treatment may be warranted because most cancer patients experience pain associated with cancer growth or cancer treatments.<sup><xref rid="bibr28-10732748241290769" ref-type="bibr">28</xref>,<xref rid="bibr29-10732748241290769" ref-type="bibr">29</xref></sup></p><p>The high probability of opioid use, even after the acute treatment phase, in some individuals is concerning because these individuals are more likely to experience opioid use disorder, abuse, and overdose deaths.<sup><xref rid="bibr30-10732748241290769" ref-type="bibr">30</xref><xref rid="bibr31-10732748241290769" ref-type="bibr"/>-<xref rid="bibr32-10732748241290769" ref-type="bibr">32</xref></sup> The high probability of persistent opioid use may reflect inappropriate use and, as stated in the introduction, can be explained from the neuropsychological perspective.<sup>
<xref rid="bibr33-10732748241290769" ref-type="bibr">33</xref>
</sup> This finding also reinforces the need for linking opioid prevention and control strategies across multiple sectors (community/social support, infrastructure, education, and employers)<sup>
<xref rid="bibr34-10732748241290769" ref-type="bibr">34</xref>
</sup> and integrating &#8220;health in all policies.&#8221;<sup><xref rid="bibr35-10732748241290769" ref-type="bibr">35</xref>,<xref rid="bibr36-10732748241290769" ref-type="bibr">36</xref></sup> Future studies need to examine and closely monitor the subgroup population more likely to be in the &#8220;persistent use&#8221; group to provide necessary strategies to begin and maintain opioid high-use recoveries.</p><p>This study found that race was one of the factors associated with being persistent opioid users. Although numerous studies have shown the relationships between race and health outcomes,<sup>
<xref rid="bibr37-10732748241290769" ref-type="bibr">37</xref>
</sup> in our case, it is strenuous to use this type of database analysis to pinpoint or establish the causal effect of race on the outcome. The reason is that the health outcome measured might also be interconnected with genetic, biological, or other factors.<sup><xref rid="bibr37-10732748241290769" ref-type="bibr">37</xref>,<xref rid="bibr38-10732748241290769" ref-type="bibr">38</xref></sup> Future studies integrating a racial viewpoint in this study area are needed to confirm the findings.<sup>
<xref rid="bibr38-10732748241290769" ref-type="bibr">38</xref>
</sup></p><p>A noteworthy finding was that several SDoH were associated with the persistent use of opioids. For example, rural residents were more likely to be persistent users of opioids. It has been reported that opioid prescribing rates are higher in rural counties than in urban areas.<sup>
<xref rid="bibr39-10732748241290769" ref-type="bibr">39</xref>
</sup> Persistent opioid use can be partially explained by the lack of affordable alternative treatment options, such as integrative health therapies for pain management in rural communities.<sup><xref rid="bibr40-10732748241290769" ref-type="bibr">40</xref>,<xref rid="bibr41-10732748241290769" ref-type="bibr">41</xref></sup> Therefore, some studies have recommended efforts to prevent and overcome opioid use issues in rural areas, including improving local access to treatment by minimizing travel distances<sup><xref rid="bibr63-10732748241290769" ref-type="bibr">42</xref>,<xref rid="bibr64-10732748241290769" ref-type="bibr">43</xref></sup> and reducing stigma through public education about the complexities of opioid use and the value of harm reduction.<sup><xref rid="bibr64-10732748241290769" ref-type="bibr">43</xref>,<xref rid="bibr65-10732748241290769" ref-type="bibr">44</xref></sup></p><p>Anxiety was associated with the persistent use of opioids over time. Anxiety and chronic pain may have a reciprocal relationship<sup>
<xref rid="bibr42-10732748241290769" ref-type="bibr">45</xref>
</sup> This reciprocity of worry and pain among people with NCPCs and cancer may create a vicious cycle that would create a higher psychological and physiological need for opioids that make them require more time to taper off.<sup><xref rid="bibr42-10732748241290769" ref-type="bibr">45</xref>,<xref rid="bibr43-10732748241290769" ref-type="bibr">46</xref></sup></p><p>Pain medications (NSAIDs, steroids, and antidepressants) were among the risk factors of persistent opioid use. Individuals prescribed NSAIDs, steroids, and antidepressants were less likely to be in the &#8220;short-term use after cancer diagnosis&#8221; group. NSAIDs, steroids, and antidepressants are often used as supportive medications for pain, along with opioids.<sup>
<xref rid="bibr44-10732748241290769" ref-type="bibr">47</xref>
</sup> It is plausible that the persistent users have greater pain intensity, necessitating additional nonopioid pain medications. Future studies are needed to explore the interactions of nonopioid pain medications and pain intensity on the persistent use of opioids.</p><p>Studies have shown that the relationship between polypharmacy (in our case, defined as &#8805;6 drugs) and opioid use is complex.<sup>
<xref rid="bibr45-10732748241290769" ref-type="bibr">48</xref>
</sup> The speculation is that opioids are associated with their adverse effects, which lead to the need for more drugs for the patients. Polypharmacy may also cause adverse effects that result in pain depending on the drugs used.<sup><xref rid="bibr45-10732748241290769" ref-type="bibr">48</xref>,<xref rid="bibr46-10732748241290769" ref-type="bibr">49</xref></sup> In addition, the side effects associated with opioids can interfere with treatments for comorbid conditions not associated with pain, especially among patients with cancer.<sup>
<xref rid="bibr47-10732748241290769" ref-type="bibr">50</xref>
</sup></p><p>This study found that patients with a higher fragmentation of care were less likely to have &#8220;persistent use.&#8221; This is in contrast to findings from a study based on data from 20% random sample of Medicare beneficiaries,<sup>
<xref rid="bibr48-10732748241290769" ref-type="bibr">51</xref>
</sup> which suggested that the risk of opioid use was higher in those seeking care from multiple providers. Our finding is also inconsistent with published studies, although not specific to older adults with any NCPCs and cancer, that have reported undesirable outcomes with fragmented care.<sup><xref rid="bibr49-10732748241290769" ref-type="bibr">52</xref>,<xref rid="bibr50-10732748241290769" ref-type="bibr">53</xref></sup> It is plausible seeing multiple providers for cancer may trigger opportunities for closer surveillance of opioid use and prescriptions. We cannot also rule out the possibility that for patients with complex chronic conditions such as cancer and NCPC, the fragmented care index may reflect appropriate care due to the need for care from multiple providers.</p><p>We also observed that higher county-level Medicare Advantage penetration rates were associated with lower odds of being in the &#8220;persistent use&#8221; group. This is consistent with the National Bureau of Economic Research report that found a reduction in the likelihood of opioid prescription in managed care prescription drug plans.<sup>
<xref rid="bibr51-10732748241290769" ref-type="bibr">54</xref>
</sup> The reduction could be due to integrated care in Medicare Advantage plans leading to improved quality of care.<sup>
<xref rid="bibr52-10732748241290769" ref-type="bibr">55</xref>
</sup> Plausible explanations for these area-level effects may be related to the so-called &#8220;spillover effects.&#8221;<sup>
<xref rid="bibr53-10732748241290769" ref-type="bibr">56</xref>
</sup> An increase in the proportion of managed care plans in an area can affect physician practice patterns both for managed care and fee-for-service patients; the resultant spillover of managed care policies eventually benefits all patients in their care.<sup>
<xref rid="bibr54-10732748241290769" ref-type="bibr">57</xref>
</sup></p><p>This study has several strengths: (1) this is the first US study to examine trajectories of prescription opioid use over time and factors associated with the trajectories among older cancer survivors with any NCPC and filled a critical knowledge gap; (2) opioid use trajectories use may be of interest to providers, patients, policymakers, and payers; (3) use of nationally representative real-world data from publicly insured older adults; and (4) comprehensive list of factors at the individual-, county-, and zip code-levels to profile the opioid trajectory groups.</p><p>Limitations of this study are: (1) As our study cohort was limited to FFS older adults, results are not generalizable to all Medicare beneficiaries; (2) This study is restricted to general opioids due to the data availability; therefore, unable to quantify the effect of different opioid class; and (3) Reliance on prescription fill data may not reflect the actual use of the medication.</p></sec><sec sec-type="conclusion" id="sec24-10732748241290769"><title>Conclusion</title><p>One in eight older adults had persistent use of opioids over time. Policies and programs to reduce chronic opioid use need to consider the intra- and inter-individual variability to reduce opioid-related morbidity and mortality.</p></sec><sec sec-type="supplementary-material" id="sec25-10732748241290769"><title>Supplemental Material</title><supplementary-material id="suppl1-10732748241290769" position="float" content-type="local-data" orientation="portrait"><caption><title><bold>Supplemental Material -</bold> Prescription Opioid Use before and after Diagnosis of Cancer Among Older Cancer Survivors With Non-Cancer Chronic Pain Conditions (NCPCs): An Application of Group-Based Trajectory Modeling (GBTM)</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sj-pdf-1-ccx-10.1177_10732748241290769.pdf" position="float" orientation="portrait"/><p>Supplemental Material for Prescription Opioid Use before and after Diagnosis of Cancer Among Older Cancer Survivors With Non-Cancer Chronic Pain Conditions (NCPCs): An Application of Group-Based Trajectory Modeling (GBTM) by Rudi Safarudin, Traci LeMasters, Salman Khan, and Usha Sambamoorthi in Cancer Control.</p></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>The collection of cancer incidence data used in this study was supported by the California Department of Public Health pursuant to California Health and Safety Code Section 103885; Centers for Disease Control and Prevention&#8217;s (CDC) National Program of Cancer Registries, under cooperative agreement 1NU58DP007156; the National Cancer Institute&#8217;s Surveillance, Epidemiology and End Results Program under contract HHSN261201800032I awarded to the University of California, San Francisco, contract HHSN261201800015I awarded to the University of Southern California, and contract HHSN261201800009I awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the author(s) and do not necessarily reflect the opinions of the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors.</p></ack><fn-group><fn fn-type="COI-statement"><p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> This research was, in part, funded by the National Institutes of Health (NIH) Agreement No. 1OT2OD032581 (Usha Sambamoorthi). The views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the NIH.</p></fn><fn fn-type="other"><p><bold>IRB Statement:</bold> West Virginia University&#8217;s Institutional Review Board (IRB) approved this study&#8217;s ethics with Acknowledgement of Not Human Subjects Research (NHSR) - protocol # 2109427002 - as no individually identifiable private information was involved.</p></fn></fn-group><fn-group><fn fn-type="supplementary-material"><p><bold>Supplemental Material:</bold> Supplemental material for this article is available online.</p></fn></fn-group><sec sec-type="orcid" id="sec29-10732748241290769"><title>ORCID iDs</title><p>Rudi Safarudin <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0003-4906-9212" ext-link-type="uri">https://orcid.org/0000-0003-4906-9212</ext-link></p><p>Traci LeMasters <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0002-6998-2650" ext-link-type="uri">https://orcid.org/0000-0002-6998-2650</ext-link></p><p>Salman Khan <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0001-5983-8965" ext-link-type="uri">https://orcid.org/0000-0001-5983-8965</ext-link></p><p>Usha Sambamoorthi <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0001-8311-1360" ext-link-type="uri">https://orcid.org/0000-0001-8311-1360</ext-link></p></sec><ref-list><title>References</title><ref id="bibr1-10732748241290769"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colvin</surname><given-names>LA</given-names></name><name name-style="western"><surname>Bull</surname><given-names>F</given-names></name><name name-style="western"><surname>Hales</surname><given-names>TG</given-names></name></person-group>. <article-title>Perioperative opioid analgesia&#8212;when is enough too much? A review of opioid-induced tolerance and hyperalgesia</article-title>. <source>Lancet</source>. <year>2019</year>;<volume>393</volume>(<issue>10180</issue>):<fpage>1558</fpage>-<lpage>1568</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(19)30430-1</pub-id><pub-id pub-id-type="pmid">30983591</pub-id></mixed-citation></ref><ref id="bibr2-10732748241290769"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>M</given-names></name><name name-style="western"><surname>Silverman</surname><given-names>S</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>H</given-names></name><name name-style="western"><surname>Patel</surname><given-names>V</given-names></name><name name-style="western"><surname>Manchikanti</surname><given-names>L</given-names></name></person-group>. <article-title>A comprehensive review of opioid-induced hyperalgesia - PubMed</article-title>. <source>Pain Physician</source>. <year>2011</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/21412369/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/21412369/</ext-link><comment>Accessed 17 August 2020.</comment><pub-id pub-id-type="pmid">21412369</pub-id></mixed-citation></ref><ref id="bibr3-10732748241290769"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>GF</given-names></name><name name-style="western"><surname>Guy</surname><given-names>GP</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K</given-names></name><name name-style="western"><surname>Mikosz</surname><given-names>CA</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name></person-group>. <article-title>Prevalence of nonopioid and opioid prescriptions among commercially insured patients with chronic pain</article-title>. <source>Pain Med</source>. <year>2019</year>;<volume>20</volume>(<issue>10</issue>):<fpage>1948</fpage>-<lpage>1954</lpage>. doi:<pub-id pub-id-type="doi">10.1093/pm/pny247</pub-id><pub-id pub-id-type="pmid">30481359</pub-id><pub-id pub-id-type="pmcid">PMC6536362</pub-id></mixed-citation></ref><ref id="bibr4-10732748241290769"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>J</given-names></name><name name-style="western"><surname>Shah</surname><given-names>D</given-names></name><name name-style="western"><surname>Sambamoorthi</surname><given-names>U</given-names></name></person-group>. <article-title>Healthcare expenditures associated with persistent opioid use among adults with chronic non-cancer pain conditions: a retrospective cohort study</article-title>. <source>J Pain Palliat Care Pharmacother</source>. <year>2020</year>;<volume>34</volume>(<issue>3</issue>):<fpage>127</fpage>-<lpage>140</lpage>. doi:<pub-id pub-id-type="doi">10.1080/15360288.2020.1734710</pub-id><pub-id pub-id-type="pmid">32186419</pub-id></mixed-citation></ref><ref id="bibr5-10732748241290769"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marshall</surname><given-names>K</given-names></name><name name-style="western"><surname>Hale</surname><given-names>D</given-names></name></person-group>. <article-title>Older adults and the opioid crisis</article-title>. <source>Home Healthc Nurse</source>. <year>2019</year>;<volume>37</volume>(<issue>2</issue>):<fpage>117</fpage>. doi:<pub-id pub-id-type="doi">10.1097/NHH.0000000000000743</pub-id><pub-id pub-id-type="pmid">30829790</pub-id></mixed-citation></ref><ref id="bibr6-10732748241290769"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larsson</surname><given-names>C</given-names></name><name name-style="western"><surname>Hansson</surname><given-names>EE</given-names></name><name name-style="western"><surname>Sundquist</surname><given-names>K</given-names></name><name name-style="western"><surname>Jakobsson</surname><given-names>U</given-names></name></person-group>. <article-title>Chronic pain in older adults: prevalence, incidence, and risk factors</article-title>. <source>Scand J Rheumatol</source>. <year>2017</year>;<volume>46</volume>(<issue>4</issue>):<fpage>317</fpage>-<lpage>325</lpage>. doi:<pub-id pub-id-type="doi">10.1080/03009742.2016.1218543</pub-id><pub-id pub-id-type="pmid">27885914</pub-id></mixed-citation></ref><ref id="bibr7-10732748241290769"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prostran</surname><given-names>M</given-names></name><name name-style="western"><surname>Vujovi&#263;</surname><given-names>KS</given-names></name><name name-style="western"><surname>Vu&#269;kovi&#263;</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Pharmacotherapy of pain in the older population: the place of opioids</article-title>. <source>Front Aging Neurosci</source>. <year>2016</year>;<volume>8</volume>(<issue>JUN</issue>):<fpage>144</fpage>. doi:<pub-id pub-id-type="doi">10.3389/FNAGI.2016.00144</pub-id><pub-id pub-id-type="pmid">27378916</pub-id><pub-id pub-id-type="pmcid">PMC4909762</pub-id></mixed-citation></ref><ref id="bibr8-10732748241290769"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramachandran</surname><given-names>S</given-names></name><name name-style="western"><surname>Salkar</surname><given-names>M</given-names></name><name name-style="western"><surname>Bentley</surname><given-names>JP</given-names></name><name name-style="western"><surname>Eriator</surname><given-names>I</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name></person-group>. <article-title>Patterns of long-term prescription opioid use among older adults in the United States: a study of medicare administrative claims data</article-title>. <source>Pain Physician</source>. <year>2021</year>;<volume>24</volume>(<issue>1</issue>):<fpage>31</fpage>-<lpage>40</lpage>. doi:<pub-id pub-id-type="doi">10.36076/ppj.2021.24.31-40</pub-id><pub-id pub-id-type="pmid">33400426</pub-id><pub-id pub-id-type="pmcid">PMC7789048</pub-id></mixed-citation></ref><ref id="bibr9-10732748241290769"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raffa</surname><given-names>RB</given-names></name><name name-style="western"><surname>Pergolizzi</surname><given-names>JV</given-names></name></person-group>. <article-title>Opioid-induced hyperalgesia: is it clinically relevant for the treatment of pain patients?</article-title><source>Pain Manag Nurs</source>. <year>2013</year>;<volume>14</volume>(<issue>3</issue>):<fpage>e67</fpage>-<lpage>e83</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pmn.2011.04.002</pub-id><pub-id pub-id-type="pmid">23972873</pub-id></mixed-citation></ref><ref id="bibr10-10732748241290769"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayhurst</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Durieux</surname><given-names>ME</given-names></name></person-group>. <article-title>Differential opioid tolerance and opioid-induced hyperalgesia: a clinical reality</article-title>. <source>Anesthesiology</source>. <year>2016</year>;<volume>124</volume>(<issue>2</issue>):<fpage>483</fpage>-<lpage>488</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ALN.0000000000000963</pub-id><pub-id pub-id-type="pmid">26594912</pub-id></mixed-citation></ref><ref id="bibr11-10732748241290769"><label>11</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Dowell</surname><given-names>D</given-names></name><name name-style="western"><surname>Haegerich</surname><given-names>TM</given-names></name><name name-style="western"><surname>Chou</surname><given-names>R</given-names></name></person-group>. <source>CDC Guideline for Prescribing Opioids for Chronic Pain &#8212; United States, 2016</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>CDC</publisher-name>. doi:<pub-id pub-id-type="doi">10.15585/mmwr.rr6501e1externalicon</pub-id></mixed-citation></ref><ref id="bibr12-10732748241290769"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dowell</surname><given-names>D</given-names></name><name name-style="western"><surname>Ragan</surname><given-names>KR</given-names></name><name name-style="western"><surname>Jones</surname><given-names>CM</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>GT</given-names></name><name name-style="western"><surname>Chou</surname><given-names>R</given-names></name></person-group>. <article-title>CDC clinical practice guideline for prescribing opioids for pain &#8212; United States, 2022</article-title>. <source>MMWR Recomm Rep (Morb Mortal Wkly Rep)</source>. <year>2022</year>;<volume>71</volume>(<issue>3</issue>):<fpage>1</fpage>-<lpage>95</lpage>. doi:<pub-id pub-id-type="doi">10.15585/MMWR.RR7103A1</pub-id><pub-id pub-id-type="pmcid">PMC9639433</pub-id><pub-id pub-id-type="pmid">36327391</pub-id></mixed-citation></ref><ref id="bibr13-10732748241290769"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>YJJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>MO</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>SO</given-names></name><name name-style="western"><surname>Winterstein</surname><given-names>AG</given-names></name></person-group>. <article-title>Trajectories of prescription opioid dose and risk of opioid-related adverse events among older Medicare beneficiaries in the United States: a nested case&#8211;control study</article-title>. <source>PLoS Med</source>. <year>2022</year>;<volume>19</volume>(<issue>3</issue>):<fpage>e1003947</fpage>. doi:<pub-id pub-id-type="doi">10.1371/JOURNAL.PMED.1003947</pub-id><pub-id pub-id-type="pmid">35290389</pub-id><pub-id pub-id-type="pmcid">PMC8923459</pub-id></mixed-citation></ref><ref id="bibr14-10732748241290769"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Binswanger</surname><given-names>IA</given-names></name><name name-style="western"><surname>Shetterly</surname><given-names>SM</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Opioid dose trajectories and associations with mortality, opioid use disorder, continued opioid therapy, and health plan disenrollment</article-title>. <source>JAMA Netw Open</source>. <year>2022</year>;<volume>5</volume>(<issue>10</issue>):<fpage>e2234671</fpage>. doi:<pub-id pub-id-type="doi">10.1001/JAMANETWORKOPEN.2022.34671</pub-id><pub-id pub-id-type="pmid">36197665</pub-id><pub-id pub-id-type="pmcid">PMC9535531</pub-id></mixed-citation></ref><ref id="bibr15-10732748241290769"><label>15</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Institute</surname><given-names>NC</given-names></name></person-group>. <source>Brief Description of SEER-Medicare Database</source>. <publisher-loc>Bethesda, MA</publisher-loc>: <publisher-name>National Institute of Health</publisher-name>; <year>2019</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://healthcaredelivery.cancer.gov/seermedicare/overview/" ext-link-type="uri">https://healthcaredelivery.cancer.gov/seermedicare/overview/</ext-link>, <comment>Accessed 6 January 2023.</comment></mixed-citation></ref><ref id="bibr16-10732748241290769"><label>16</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>US-DHHR</collab></person-group>. <article-title>Area health resources files. Health resources and services administration</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://data.hrsa.gov/topics/health-workforce/ahrf" ext-link-type="uri">https://data.hrsa.gov/topics/health-workforce/ahrf</ext-link>. <comment>Accessed 6 September 2022.</comment></mixed-citation></ref><ref id="bibr17-10732748241290769"><label>17</label><mixed-citation publication-type="other"><article-title>Clinical classifications software (CCS) for ICD-9-CM</article-title>. <comment>Accessed January 22, 2023.</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp" ext-link-type="uri">https://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp</ext-link></mixed-citation></ref><ref id="bibr18-10732748241290769"><label>18</label><mixed-citation publication-type="other"><article-title>Clinical classifications software (CCS) for ICD-10-PCS (beta version)</article-title>. <comment>Accessed January 22, 2023.</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hcup-us.ahrq.gov/toolssoftware/ccs10/ccs10.jsp" ext-link-type="uri">https://www.hcup-us.ahrq.gov/toolssoftware/ccs10/ccs10.jsp</ext-link></mixed-citation></ref><ref id="bibr19-10732748241290769"><label>19</label><mixed-citation publication-type="other"><article-title>Generic name | ResDAC</article-title>. <comment>Accessed January 23, 2023.</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://resdac.org/cms-data/variables/generic-name" ext-link-type="uri">https://resdac.org/cms-data/variables/generic-name</ext-link></mixed-citation></ref><ref id="bibr20-10732748241290769"><label>20</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>KK</given-names></name></person-group><article-title>Park-Park&#8217;s textbook of preventive and social medicine-banarsidas bhanot</article-title> (<year>2015</year>) <source>Ayurveda | Epidemiology</source>. <publisher-loc>Jabalpur, India</publisher-loc>: <publisher-name>Bhanot</publisher-name>. <comment>Accessed May 20, 2021. </comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.scribd.com/document/326461178/K-Park-Park-s-Textbook-of-Preventive-and-Social-Medicine-Banarsidas-Bhanot-2015-1" ext-link-type="uri">https://www.scribd.com/document/326461178/K-Park-Park-s-Textbook-of-Preventive-and-Social-Medicine-Banarsidas-Bhanot-2015-1</ext-link></mixed-citation></ref><ref id="bibr21-10732748241290769"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saultz</surname><given-names>JW</given-names></name></person-group>. <article-title>Defining and measuring interpersonal continuity of care</article-title>. <source>Ann Fam Med</source>. <year>2003</year>;<volume>1</volume>(<issue>3</issue>):<fpage>134</fpage>-<lpage>143</lpage>. doi:<pub-id pub-id-type="doi">10.1370/AFM.23</pub-id><pub-id pub-id-type="pmid">15043374</pub-id><pub-id pub-id-type="pmcid">PMC1466595</pub-id></mixed-citation></ref><ref id="bibr22-10732748241290769"><label>22</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Nagin</surname><given-names>DS</given-names></name></person-group>. <source>Group-Based Modeling of Development</source>. <publisher-loc>Cambridge, MA</publisher-loc>: <publisher-name>Harvard University Press</publisher-name>; <year>2005</year>.</mixed-citation></ref><ref id="bibr23-10732748241290769"><label>23</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Bryk</surname><given-names>AS</given-names></name><name name-style="western"><surname>Raudenbush</surname></name></person-group>, <source><italic toggle="yes">SW.</italic> Hierarchical linear models: Applications and data analysis methods</source>. <publisher-name>Sage Publications, Inc. American Psychological Association-PsycNet</publisher-name>. <year>1992</year>. <comment>Accessed</comment><date-in-citation>January 26, 2023</date-in-citation>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://psycnet.apa.org/record/1992-97494-000" ext-link-type="uri">https://psycnet.apa.org/record/1992-97494-000</ext-link></mixed-citation></ref><ref id="bibr24-10732748241290769"><label>24</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Equator</collab></person-group>. <source>Selecting the appropriate reporting guideline for your article | EQUATOR Network. UK EQUATOR Centre - Centre for Statistics in Medicine (CSM)</source>, <publisher-name>NDORMS, University of Oxford</publisher-name>. <publisher-loc>UK</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.equator-network.org/toolkits/selecting-the-appropriate-reporting-guideline/" ext-link-type="uri">https://www.equator-network.org/toolkits/selecting-the-appropriate-reporting-guideline/</ext-link>. <comment>Accessed</comment><date-in-citation>August 5, 2024</date-in-citation>.</mixed-citation></ref><ref id="bibr25-10732748241290769"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>von Elm</surname><given-names>E</given-names></name><name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name><name name-style="western"><surname>Egger</surname><given-names>M</given-names></name><name name-style="western"><surname>Pocock</surname><given-names>SJ</given-names></name><name name-style="western"><surname>G&#248;tzsche</surname><given-names>PC</given-names></name><name name-style="western"><surname>Vandenbroucke</surname><given-names>JP</given-names></name><collab>STROBE Initiative</collab></person-group>. <article-title>The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies</article-title>. <source>J Clin Epidemiol</source>. <year>2008</year>;<volume>61</volume>(<issue>4</issue>):<fpage>344</fpage>-<lpage>349</lpage>. doi:<pub-id pub-id-type="doi">10.1016/J.JCLINEPI.2007.11.008</pub-id><pub-id pub-id-type="pmid">18313558</pub-id></mixed-citation></ref><ref id="bibr26-10732748241290769"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagin</surname><given-names>DS</given-names></name></person-group>. <article-title>Analyzing developmental trajectories: a semiparametric, group-based approach</article-title>. <source>Psychol Methods</source>. <year>1999</year>;<volume>4</volume>(<issue>2</issue>):<fpage>139</fpage>-<lpage>157</lpage>. doi:<pub-id pub-id-type="doi">10.1037/1082-989X.4.2.139</pub-id><pub-id pub-id-type="pmid">11285809</pub-id></mixed-citation></ref><ref id="bibr27-10732748241290769"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagin</surname><given-names>DS</given-names></name><name name-style="western"><surname>Odgers</surname><given-names>CL</given-names></name></person-group>. <article-title>Group-based trajectory modeling in clinical research</article-title>. <source>Annu Rev Clin Psychol</source>. <year>2010</year>;<volume>6</volume>:<fpage>109</fpage>-<lpage>138</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev.clinpsy.121208.131413</pub-id><pub-id pub-id-type="pmid">20192788</pub-id></mixed-citation></ref><ref id="bibr28-10732748241290769"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Novy</surname><given-names>DM</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>DV</given-names></name><name name-style="western"><surname>Koyyalagunta</surname><given-names>D</given-names></name><name name-style="western"><surname>Cata</surname><given-names>JP</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>P</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>K</given-names></name></person-group>. <article-title>Pain, opioid therapy, and survival: a needed discussion</article-title>. <source>Pain</source>. <year>2020</year>;<volume>161</volume>(<issue>3</issue>):<fpage>496</fpage>-<lpage>501</lpage>. doi:<pub-id pub-id-type="doi">10.1097/J.PAIN.0000000000001736</pub-id><pub-id pub-id-type="pmid">31693537</pub-id><pub-id pub-id-type="pmcid">PMC7017938</pub-id></mixed-citation></ref><ref id="bibr29-10732748241290769"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Page</surname><given-names>R</given-names></name><name name-style="western"><surname>Blanchard</surname><given-names>E</given-names></name></person-group>. <article-title>Opioids and cancer pain: patients&#8217; needs and access challenges</article-title>. <source>J Oncol Pract</source>. <year>2019</year>;<volume>15</volume>(<issue>5</issue>):<fpage>229</fpage>-<lpage>231</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JOP.19.00081</pub-id><pub-id pub-id-type="pmid">31013181</pub-id></mixed-citation></ref><ref id="bibr30-10732748241290769"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karila</surname><given-names>L</given-names></name><name name-style="western"><surname>Marillier</surname><given-names>M</given-names></name><name name-style="western"><surname>Chaumette</surname><given-names>B</given-names></name><name name-style="western"><surname>Billieux</surname><given-names>J</given-names></name><name name-style="western"><surname>Franchitto</surname><given-names>N</given-names></name><name name-style="western"><surname>Benyamina</surname><given-names>A</given-names></name></person-group>. <article-title>New synthetic opioids: Part of a new addiction landscape</article-title>. <source>Neurosci Biobehav Rev</source>. <year>2019</year>;<volume>106</volume>:<fpage>133</fpage>-<lpage>140</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neubiorev.2018.06.010</pub-id><pub-id pub-id-type="pmid">30217656</pub-id></mixed-citation></ref><ref id="bibr31-10732748241290769"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blendon</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Benson</surname><given-names>JM</given-names></name></person-group>. <article-title>The public and the opioid-abuse epidemic</article-title>. <source>N Engl J Med</source>. <year>2018</year>;<volume>378</volume>(<issue>5</issue>):<fpage>407</fpage>-<lpage>411</lpage>. doi:<pub-id pub-id-type="doi">10.1056/nejmp1714529</pub-id><pub-id pub-id-type="pmid">29298128</pub-id></mixed-citation></ref><ref id="bibr32-10732748241290769"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bohnert</surname><given-names>ASB</given-names></name><name name-style="western"><surname>Valenstein</surname><given-names>M</given-names></name><name name-style="western"><surname>Bair</surname><given-names>MJ</given-names></name></person-group>, <etal>et al.</etal><article-title>Association between opioid prescribing patterns and opioid overdose-related deaths</article-title>. <source>JAMA</source>. <year>2011</year>;<volume>305</volume>(<issue>13</issue>):<fpage>1315</fpage>-<lpage>1321</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2011.370</pub-id><pub-id pub-id-type="pmid">21467284</pub-id></mixed-citation></ref><ref id="bibr33-10732748241290769"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volkow</surname><given-names>ND</given-names></name><name name-style="western"><surname>McLellan</surname><given-names>AT</given-names></name></person-group>. <article-title>Opioid abuse in chronic pain&#8212;misconceptions and mitigation strategies</article-title>. <source>N Engl J Med</source>. <year>2016</year>;<volume>374</volume>(<issue>13</issue>):<fpage>1253</fpage>-<lpage>1263</lpage>.<pub-id pub-id-type="pmid">27028915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra1507771</pub-id></mixed-citation></ref><ref id="bibr34-10732748241290769"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>ARC</collab></person-group>. <article-title>Investments supporting partnerships in recovery ecosystems initiative - appalachian regional commission</article-title>. <source>Appalachian Regional Commission</source>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.arc.gov/sud/" ext-link-type="uri">https://www.arc.gov/sud/</ext-link><comment>Accessed 25 January 2023.</comment></mixed-citation></ref><ref id="bibr35-10732748241290769"><label>35</label><mixed-citation publication-type="other"><article-title>Health in all policies</article-title>. <comment>Accessed January 26, 2023.</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.apha.org/topics-and-issues/health-in-all-policies" ext-link-type="uri">https://www.apha.org/topics-and-issues/health-in-all-policies</ext-link></mixed-citation></ref><ref id="bibr36-10732748241290769"><label>36</label><mixed-citation publication-type="book"><source>Health in All Policies | AD for Policy and Strategy</source>. <publisher-loc>Atlanta, Georgia, United States</publisher-loc>: <publisher-name>CDC</publisher-name>. <comment>Accessed January 26, 2023.</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/policy/hiap/index.html" ext-link-type="uri">https://www.cdc.gov/policy/hiap/index.html</ext-link></mixed-citation></ref><ref id="bibr37-10732748241290769"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flanagin</surname><given-names>A</given-names></name><name name-style="western"><surname>Frey</surname><given-names>T</given-names></name><name name-style="western"><surname>Christiansen</surname><given-names>SL</given-names></name><name name-style="western"><surname>Bauchner</surname><given-names>H</given-names></name></person-group>. <article-title>The reporting of race and ethnicity in medical and science journals: comments invited</article-title>. <source>JAMA</source>. <year>2021</year>;<volume>325</volume>(<issue>11</issue>):<fpage>1049</fpage>-<lpage>1052</lpage>. doi:<pub-id pub-id-type="doi">10.1001/JAMA.2021.2104</pub-id><pub-id pub-id-type="pmid">33616604</pub-id></mixed-citation></ref><ref id="bibr38-10732748241290769"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyd</surname><given-names>RW</given-names></name><name name-style="western"><surname>Lindo</surname><given-names>EG</given-names></name><name name-style="western"><surname>Weeks</surname><given-names>LD</given-names></name><name name-style="western"><surname>McLemore</surname><given-names>MR</given-names></name></person-group>. <article-title>On racism: a new standard for publishing on racial health inequities</article-title>. <source>Health Affairs Forefront</source><year>2020</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.healthaffairs.org/content/forefront/racism-new-standard-publishing-racial-health-inequities" ext-link-type="uri">https://www.healthaffairs.org/content/forefront/racism-new-standard-publishing-racial-health-inequities</ext-link>.</mixed-citation></ref><ref id="bibr39-10732748241290769"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a</surname><given-names>MC</given-names></name><name name-style="western"><surname>Heilig</surname><given-names>CM</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SH</given-names></name></person-group>, <etal>et al.</etal><article-title>Opioid prescribing rates in nonmetropolitan and metropolitan counties among primary care providers using an electronic health record system &#8212; United States, 2014&#8211;2017</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2019</year>;<volume>68</volume>(<issue>2</issue>):<fpage>25</fpage>-<lpage>30</lpage>. doi:<pub-id pub-id-type="doi">10.15585/MMWR.MM6802A1</pub-id><pub-id pub-id-type="pmid">30653483</pub-id><pub-id pub-id-type="pmcid">PMC6336190</pub-id></mixed-citation></ref><ref id="bibr40-10732748241290769"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guy</surname><given-names>GP</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K</given-names></name><name name-style="western"><surname>Bohm</surname><given-names>MK</given-names></name></person-group>, <etal>et al.</etal><article-title>Vital signs: changes in opioid prescribing in the United States, 2006&#8211;2015</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2019</year>;<volume>66</volume>(<issue>26</issue>):<fpage>697</fpage>-<lpage>704</lpage>. doi:<pub-id pub-id-type="doi">10.15585/MMWR.MM6626A4</pub-id><pub-id pub-id-type="pmcid">PMC5726238</pub-id><pub-id pub-id-type="pmid">28683056</pub-id></mixed-citation></ref><ref id="bibr41-10732748241290769"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palombi</surname><given-names>LC</given-names></name><name name-style="western"><surname>St Hill</surname><given-names>CA</given-names></name><name name-style="western"><surname>Lipsky</surname><given-names>MS</given-names></name><name name-style="western"><surname>Swanoski</surname><given-names>MT</given-names></name><name name-style="western"><surname>Lutfiyya</surname><given-names>MN</given-names></name></person-group>. <article-title>A scoping review of opioid misuse in the rural United States</article-title>. <source>Ann Epidemiol</source>. <year>2018</year>;<volume>28</volume>(<issue>9</issue>):<fpage>641</fpage>-<lpage>652</lpage>. doi:<pub-id pub-id-type="doi">10.1016/J.ANNEPIDEM.2018.05.008</pub-id><pub-id pub-id-type="pmid">29921551</pub-id></mixed-citation></ref><ref id="bibr63-10732748241290769"><label>42</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Bonny</surname><given-names>AE</given-names></name><name name-style="western"><surname>Nahata</surname><given-names>MC</given-names></name></person-group>. <article-title>Strategies to Improve Access to Care for Patients With Opioid Use Disorder</article-title>. <pub-id pub-id-type="doi">10.1177/10600280241273258</pub-id>. September 2024. doi:<pub-id pub-id-type="doi">10.1177/10600280241273258</pub-id><pub-id pub-id-type="pmid">39229941</pub-id></mixed-citation></ref><ref id="bibr64-10732748241290769"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stopka</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Estadt</surname><given-names>AT</given-names></name><name name-style="western"><surname>Leichtling</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>. <article-title>Barriers to opioid use disorder treatment among people who use drugs in the rural United States: A qualitative, multi-site study</article-title>. <source>Soc Sci Med</source>. <year>2024</year>;<volume>346</volume>:<fpage>116660</fpage>. doi:<pub-id pub-id-type="doi">10.1016/J.SOCSCIMED.2024.116660</pub-id><pub-id pub-id-type="pmid">38484417</pub-id><pub-id pub-id-type="pmcid">PMC10997882</pub-id></mixed-citation></ref><ref id="bibr65-10732748241290769"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ezell</surname><given-names>JM</given-names></name><name name-style="western"><surname>Walters</surname><given-names>S</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>SR</given-names></name></person-group>, <etal>et al</etal>. <article-title>Stigmatize the use, not the user? Attitudes on opioid use, drug injection, treatment, and overdose prevention in rural communities</article-title>. <source>Soc Sci Med</source>. <year>2021</year>;<volume>268</volume>:<fpage>113470</fpage>. doi:<pub-id pub-id-type="doi">10.1016/J.SOCSCIMED.2020.113470</pub-id><pub-id pub-id-type="pmid">33253992</pub-id><pub-id pub-id-type="pmcid">PMC7755701</pub-id></mixed-citation></ref><ref id="bibr42-10732748241290769"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thielking</surname><given-names>PD</given-names></name></person-group>. <article-title>Cancer pain and anxiety</article-title>. <source>Curr Pain Headache Rep</source>. <year>2003</year>;<volume>7</volume>(<issue>4</issue>):<fpage>249</fpage>-<lpage>261</lpage>. doi:<pub-id pub-id-type="doi">10.1007/S11916-003-0045-X</pub-id><pub-id pub-id-type="pmid">12828874</pub-id></mixed-citation></ref><ref id="bibr43-10732748241290769"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langdon</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Dove</surname><given-names>K</given-names></name><name name-style="western"><surname>Ramsey</surname><given-names>S</given-names></name></person-group>. <article-title>Comorbidity of opioid-related and anxiety-related symptoms and disorders</article-title>. <source>Curr Opin Psychol</source>. <year>2019</year>;<volume>30</volume>:<fpage>17</fpage>-<lpage>23</lpage>. doi:<pub-id pub-id-type="doi">10.1016/J.COPSYC.2018.12.020</pub-id><pub-id pub-id-type="pmid">30711906</pub-id><pub-id pub-id-type="pmcid">PMC6609499</pub-id></mixed-citation></ref><ref id="bibr44-10732748241290769"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>BA</given-names></name><name name-style="western"><surname>Wahner-Roedler</surname><given-names>DL</given-names></name><name name-style="western"><surname>Chon</surname><given-names>TY</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>L</given-names></name></person-group>. <article-title>The modified WHO analgesic ladder: is it appropriate for chronic non-cancer pain?</article-title><source>J Pain Res</source>. <year>2020</year>;<volume>13</volume>:<fpage>411</fpage>-<lpage>417</lpage>. doi:<pub-id pub-id-type="doi">10.2147/JPR.S244173</pub-id><pub-id pub-id-type="pmid">32110089</pub-id><pub-id pub-id-type="pmcid">PMC7038776</pub-id></mixed-citation></ref><ref id="bibr45-10732748241290769"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matos</surname><given-names>A</given-names></name><name name-style="western"><surname>Bankes</surname><given-names>DL</given-names></name><name name-style="western"><surname>Bain</surname><given-names>KT</given-names></name><name name-style="western"><surname>Ballinghoff</surname><given-names>T</given-names></name><name name-style="western"><surname>Turgeon</surname><given-names>J</given-names></name></person-group>. <article-title>Opioids, polypharmacy, and drug interactions: a technological paradigm shift is needed to ameliorate the ongoing opioid epidemic</article-title>. <source>Pharmacy: Journal of Pharmacy Education and Practice</source>. <year>2020</year>;<volume>8</volume>(<issue>3</issue>):<fpage>154</fpage>. doi:<pub-id pub-id-type="doi">10.3390/PHARMACY8030154</pub-id><pub-id pub-id-type="pmid">32854271</pub-id><pub-id pub-id-type="pmcid">PMC7559875</pub-id></mixed-citation></ref><ref id="bibr46-10732748241290769"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giummarra</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Allen</surname><given-names>AR</given-names></name><name name-style="western"><surname>Pichler</surname><given-names>AS</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>CA</given-names></name></person-group>. <article-title>Polypharmacy and chronic pain: harm exposure is not all about the opioids</article-title>. <source>Pain Med</source>. <year>2015</year>;<volume>16</volume>(<issue>3</issue>):<fpage>472</fpage>-<lpage>479</lpage>. doi:<pub-id pub-id-type="doi">10.1111/PME.12586/SUPPINFO</pub-id><pub-id pub-id-type="pmid">25280054</pub-id></mixed-citation></ref><ref id="bibr47-10732748241290769"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kotlinska-Lemieszek</surname><given-names>A</given-names></name><name name-style="western"><surname>Paulsen</surname><given-names>&#216;</given-names></name><name name-style="western"><surname>Kaasa</surname><given-names>S</given-names></name><name name-style="western"><surname>Klepstad</surname><given-names>P</given-names></name></person-group>. <article-title>Polypharmacy in patients with advanced cancer and pain: a European cross-sectional study of 2282 patients</article-title>. <source>J Pain Symptom Manag</source>. <year>2014</year>;<volume>48</volume>(<issue>6</issue>):<fpage>1145</fpage>-<lpage>1159</lpage>. doi:<pub-id pub-id-type="doi">10.1016/J.JPAINSYMMAN.2014.03.008</pub-id><pub-id pub-id-type="pmid">24780183</pub-id></mixed-citation></ref><ref id="bibr48-10732748241290769"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jena</surname><given-names>AB</given-names></name><name name-style="western"><surname>Goldman</surname><given-names>D</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>L</given-names></name><name name-style="western"><surname>Karaca-Mandic</surname><given-names>P</given-names></name></person-group>. <article-title>Opioid prescribing by multiple providers in Medicare: retrospective observational study of insurance claims</article-title>. <source>BMJ</source>. <year>2014</year>;<volume>348</volume>:<fpage>g1393</fpage>. doi:<pub-id pub-id-type="doi">10.1136/BMJ.G1393</pub-id><pub-id pub-id-type="pmid">24553363</pub-id><pub-id pub-id-type="pmcid">PMC3928962</pub-id></mixed-citation></ref><ref id="bibr49-10732748241290769"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juo</surname><given-names>YY</given-names></name><name name-style="western"><surname>Sanaiha</surname><given-names>Y</given-names></name><name name-style="western"><surname>Khrucharoen</surname><given-names>U</given-names></name><name name-style="western"><surname>Chang</surname><given-names>BH</given-names></name><name name-style="western"><surname>Dutson</surname><given-names>E</given-names></name><name name-style="western"><surname>Benharash</surname><given-names>P</given-names></name></person-group>. <article-title>Care fragmentation is associated with increased short-term mortality during postoperative readmissions: a systematic review and meta-analysis</article-title>. <source>Surgery</source>. <year>2019</year>;<volume>165</volume>(<issue>3</issue>):<fpage>501</fpage>-<lpage>509</lpage>. doi:<pub-id pub-id-type="doi">10.1016/J.SURG.2018.08.021</pub-id><pub-id pub-id-type="pmid">30638610</pub-id></mixed-citation></ref><ref id="bibr50-10732748241290769"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castro-S&#225;nchez</surname><given-names>E</given-names></name><name name-style="western"><surname>Charani</surname><given-names>E</given-names></name><name name-style="western"><surname>Drumright</surname><given-names>LN</given-names></name><name name-style="western"><surname>Sevdalis</surname><given-names>N</given-names></name><name name-style="western"><surname>Shah</surname><given-names>N</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>AH</given-names></name></person-group>. <article-title>Fragmentation of care threatens patient safety in peripheral vascular catheter management in acute care--a qualitative study</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>1</issue>):<fpage>e86167</fpage>. doi:<pub-id pub-id-type="doi">10.1371/JOURNAL.PONE.0086167</pub-id><pub-id pub-id-type="pmid">24454958</pub-id><pub-id pub-id-type="pmcid">PMC3891872</pub-id></mixed-citation></ref><ref id="bibr51-10732748241290769"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>LC</given-names></name><name name-style="western"><surname>Bundorf</surname><given-names>MK</given-names></name><name name-style="western"><surname>Kessler</surname><given-names>DP</given-names></name></person-group>. <article-title>The effects of medicare advantage on opioid use</article-title>. <source>J Health Econ</source>. <year>2020</year>;<volume>70</volume>:<fpage>102278</fpage>. doi:<pub-id pub-id-type="doi">10.1016/J.JHEALECO.2019.102278</pub-id><pub-id pub-id-type="pmid">31972536</pub-id><pub-id pub-id-type="pmcid">PMC7181702</pub-id></mixed-citation></ref><ref id="bibr52-10732748241290769"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DuGoff</surname><given-names>E</given-names></name><name name-style="western"><surname>Tabak</surname><given-names>R</given-names></name><name name-style="western"><surname>Diduch</surname><given-names>T</given-names></name><name name-style="western"><surname>Garth</surname><given-names>V</given-names></name></person-group>. <article-title>Quality, health, and spending in medicare advantage and traditional medicare</article-title>. <source>Am J Manag Care</source>. <year>2021</year>;<volume>27</volume>(<issue>9</issue>):<fpage>395</fpage>-<lpage>400</lpage>. doi:<pub-id pub-id-type="doi">10.37765/AJMC.2021.88641</pub-id><pub-id pub-id-type="pmid">34533909</pub-id></mixed-citation></ref><ref id="bibr53-10732748241290769"><label>56</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Kane</surname><given-names>RL</given-names></name><name name-style="western"><surname>Butler</surname><given-names>M</given-names></name><name name-style="western"><surname>Fink</surname><given-names>HA</given-names></name></person-group>, <etal>et al.</etal><source>Interventions to Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer&#8217;s-type Dementia</source>. <publisher-loc>Rockville, MA</publisher-loc>: <publisher-name>Agency for Healthcare Research and Quality (US)</publisher-name>; <year>2017</year>.<pub-id pub-id-type="pmid">28759193</pub-id></mixed-citation></ref><ref id="bibr54-10732748241290769"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baicker</surname><given-names>K</given-names></name><name name-style="western"><surname>Chernew</surname><given-names>ME</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>JA</given-names></name></person-group>. <article-title>The spillover effects of medicare managed care: medicare advantage and hospital utilization</article-title>. <source>J Health Econ</source>. <year>2013</year>;<volume>32</volume>(<issue>6</issue>):<fpage>1289</fpage>-<lpage>1300</lpage>. doi:<pub-id pub-id-type="doi">10.1016/J.JHEALECO.2013.09.005</pub-id><pub-id pub-id-type="pmid">24308880</pub-id><pub-id pub-id-type="pmcid">PMC3855665</pub-id></mixed-citation></ref></ref-list><app-group><app id="app1-10732748241290769"><label>Appendix 1.</label><title>Baseline Characteristics of Older Medicare Beneficiaries with any NCPC Diagnosed with Breast, Colorectal, Prostate Cancers, or NHL Linked Surveillance, Epidemiology, and End Results (SEER) and Medicare, 2007-2015.</title><p>
<table-wrap position="anchor" id="table5-10732748241290769" orientation="portrait"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="table5-10732748241290769" position="float" orientation="portrait" xlink:href="10.1177_10732748241290769-table5.jpg"/><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="2" colspan="1">ALL</th><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">%</th></tr><tr><th align="left" rowspan="1" colspan="1">35,071</th><th align="center" rowspan="1" colspan="1">100</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="3" rowspan="1">Sex</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Female</td><td align="center" rowspan="1" colspan="1">20,527</td><td align="center" rowspan="1" colspan="1">58.5</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Male</td><td align="center" rowspan="1" colspan="1">14,544</td><td align="center" rowspan="1" colspan="1">41.5</td></tr><tr><td align="left" colspan="3" rowspan="1">Race and ethnicity</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-hispanic white</td><td align="center" rowspan="1" colspan="1">26,605</td><td align="center" rowspan="1" colspan="1">75.9</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-hispanic black</td><td align="center" rowspan="1" colspan="1">3,200</td><td align="center" rowspan="1" colspan="1">9.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Latino/hispanic</td><td align="center" rowspan="1" colspan="1">2,710</td><td align="center" rowspan="1" colspan="1">7.7</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Other races</td><td align="center" rowspan="1" colspan="1">2,070</td><td align="center" rowspan="1" colspan="1">5.9</td></tr><tr><td align="left" colspan="3" rowspan="1">Marital status</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Married</td><td align="center" rowspan="1" colspan="1">17,214</td><td align="center" rowspan="1" colspan="1">49.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Wid./Sep/Div</td><td align="center" rowspan="1" colspan="1">11,246</td><td align="center" rowspan="1" colspan="1">32.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Never married</td><td align="center" rowspan="1" colspan="1">2,943</td><td align="center" rowspan="1" colspan="1">8.4</td></tr><tr><td align="left" colspan="3" rowspan="1">Substance abuse</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">1,756</td><td align="center" rowspan="1" colspan="1">5.0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">33,315</td><td align="center" rowspan="1" colspan="1">95.0</td></tr><tr><td align="left" colspan="3" rowspan="1">Type of cancer</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Breast</td><td align="center" rowspan="1" colspan="1">14,744</td><td align="center" rowspan="1" colspan="1">42.0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Prostate</td><td align="center" rowspan="1" colspan="1">11,503</td><td align="center" rowspan="1" colspan="1">32.8</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Colorectal</td><td align="center" rowspan="1" colspan="1">5,964</td><td align="center" rowspan="1" colspan="1">17.0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-hodgkin lymphoma</td><td align="center" rowspan="1" colspan="1">2,860</td><td align="center" rowspan="1" colspan="1">8.2</td></tr><tr><td align="left" colspan="3" rowspan="1">Cancer stage</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Early stage</td><td align="center" rowspan="1" colspan="1">27,953</td><td align="center" rowspan="1" colspan="1">79.7</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Late stage</td><td align="center" rowspan="1" colspan="1">4,862</td><td align="center" rowspan="1" colspan="1">13.9</td></tr><tr><td align="left" colspan="3" rowspan="1">Comorbidity (&gt;=2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">27,811</td><td align="center" rowspan="1" colspan="1">79.3</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">7,260</td><td align="center" rowspan="1" colspan="1">20.7</td></tr><tr><td align="left" colspan="3" rowspan="1">Depression</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">3,996</td><td align="center" rowspan="1" colspan="1">11.4</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">31,075</td><td align="center" rowspan="1" colspan="1">88.6</td></tr><tr><td align="left" colspan="3" rowspan="1">Anxiety</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">3,187</td><td align="center" rowspan="1" colspan="1">9.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">31,884</td><td align="center" rowspan="1" colspan="1">90.9</td></tr><tr><td align="left" colspan="3" rowspan="1">Prescription NSAIDs</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">10,267</td><td align="center" rowspan="1" colspan="1">29.3</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">24,804</td><td align="center" rowspan="1" colspan="1">70.7</td></tr><tr><td align="left" colspan="3" rowspan="1">Steroids</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">16,242</td><td align="center" rowspan="1" colspan="1">46.3</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">18,829</td><td align="center" rowspan="1" colspan="1">53.7</td></tr><tr><td align="left" colspan="3" rowspan="1">Antidepressant</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">8,303</td><td align="center" rowspan="1" colspan="1">23.7</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">26,768</td><td align="center" rowspan="1" colspan="1">76.3</td></tr><tr><td align="left" colspan="3" rowspan="1">Benzodiazepine</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">2,021</td><td align="center" rowspan="1" colspan="1">5.8</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">33,050</td><td align="center" rowspan="1" colspan="1">94.2</td></tr><tr><td align="left" colspan="3" rowspan="1">Polypharmacy (&#8805;6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">16,442</td><td align="center" rowspan="1" colspan="1">46.9</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">18,629</td><td align="center" rowspan="1" colspan="1">53.1</td></tr><tr><td align="left" colspan="3" rowspan="1">Medicaid dual eligibility</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">4,284</td><td align="center" rowspan="1" colspan="1">12.2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">30,787</td><td align="center" rowspan="1" colspan="1">87.8</td></tr><tr><td align="left" colspan="3" rowspan="1">Pain specialist visit</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">7,770</td><td align="center" rowspan="1" colspan="1">22.2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">27,301</td><td align="center" rowspan="1" colspan="1">77.8</td></tr><tr><td align="left" colspan="3" rowspan="1">Diagnosis year</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;2009</td><td align="center" rowspan="1" colspan="1">6,259</td><td align="center" rowspan="1" colspan="1">17.8</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;2010</td><td align="center" rowspan="1" colspan="1">6,589</td><td align="center" rowspan="1" colspan="1">18.8</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;2011</td><td align="center" rowspan="1" colspan="1">6,892</td><td align="center" rowspan="1" colspan="1">19.7</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;2012</td><td align="center" rowspan="1" colspan="1">7,224</td><td align="center" rowspan="1" colspan="1">20.6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;2013</td><td align="center" rowspan="1" colspan="1">8,107</td><td align="center" rowspan="1" colspan="1">23.1</td></tr><tr><td align="left" colspan="3" rowspan="1">Metropolitan status</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Metropolitan</td><td align="center" rowspan="1" colspan="1">29,528</td><td align="center" rowspan="1" colspan="1">84.2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Non-metropolitan</td><td align="center" rowspan="1" colspan="1">4,823</td><td align="center" rowspan="1" colspan="1">13.8</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Rural</td><td align="center" rowspan="1" colspan="1">697</td><td align="center" rowspan="1" colspan="1">2.0</td></tr><tr><td align="left" colspan="3" rowspan="1">Region</td></tr><tr><td align="left" rowspan="1" colspan="1">&#160;&#160;Northeast</td><td align="center" rowspan="1" colspan="1">7,065</td><td align="center" rowspan="1" colspan="1">20.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;South</td><td align="center" rowspan="1" colspan="1">8,158</td><td align="center" rowspan="1" colspan="1">23.3</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;North central</td><td align="center" rowspan="1" colspan="1">4,294</td><td align="center" rowspan="1" colspan="1">12.2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;West</td><td align="center" rowspan="1" colspan="1">15,554</td><td align="center" rowspan="1" colspan="1">44.4</td></tr></tbody></table><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">SD</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">&#8195;Age</td><td align="center" rowspan="1" colspan="1">75.95</td><td align="center" rowspan="1" colspan="1">6.31</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Fragmented care index (x 10)</td><td align="center" rowspan="1" colspan="1">7.3</td><td align="center" rowspan="1" colspan="1">2.48</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Numaber of physical comorbidities</td><td align="center" rowspan="1" colspan="1">3.05</td><td align="center" rowspan="1" colspan="1">1.91</td></tr><tr><td align="left" colspan="3" rowspan="1">Neighborhood characteristics</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Zip code level median income</td><td align="center" rowspan="1" colspan="1">$41,992.13</td><td align="center" rowspan="1" colspan="1">$25,038</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Zip code level education (% less than HS education)</td><td align="center" rowspan="1" colspan="1">24.12%</td><td align="center" rowspan="1" colspan="1">16.73%</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Percentage below poverty line</td><td align="center" rowspan="1" colspan="1">14.47</td><td align="center" rowspan="1" colspan="1">12.43</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;% medicare advantage penetration</td><td align="center" rowspan="1" colspan="1">24.99</td><td align="center" rowspan="1" colspan="1">12.84</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Note: Based on 35,071 adults with NCPCs (67 years at cancer diagnosis) or older, diagnosed with incident primary breast, prostate, colorectal cancers, and NHL between 2009 and 2015, continuously enrolled in Fee-for-Service Medicare Parts A and B for 24-month, and continuously enrolled in Medicare part D for 12 months before and 24 months after cancer diagnosis.</p></fn><fn><p>Abbreviations: NHL: Non-Hodgkin Lymphoma, Wid/Sep/Div : Widow/Separate/Divorce, HS : High School, SD: Standard Deviation.</p></fn></table-wrap-foot></table-wrap>
</p></app></app-group></back></article></pmc-articleset>